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ABSTRACT 
Jayme K. Warischalk: Uncovering structural components of the adeno-associated viral 
capsid that can be modified to improve clinical gene therapy outcomes 
(Under the direction of Richard Jude Samulski)
Recombinant adeno-associated virus (rAAV) has become increasingly employed 
as a gene delivery vector in clinical trials. Despite several notable instances of success 
using rAAV-based gene therapy, a number of obstacles must be overcome before such 
therapy will be widely utilized for the treatment of disease. These include the limited 
transduction efficiency of rAAV, the promiscuity of viral biodistribution following systemic 
administration, and the prevalence of neutralizing antibodies against the rAAV capsid 
that exists within the population at large, hindering the use of gene therapy in many 
patients. Each of these issues ultimately necessitates the administration of high doses 
of vector to achieve therapeutic effect – a costly prospect when feasible. Engineering 
the rAAV capsid protein to overcome these hurdles is an emerging strategy to better 
optimize the virion for translational studies. To develop new logical approaches to 
capsid engineering, it is necessary to uncover the structure-function relationships of 
various features of the rAAV capsid protein. In this dissertation, computational analysis 
of capsid crystal structure data was used to guide the molecular dissection of a single 
loop on the capsid surface, termed variable region 1 (VR1). We discovered that the 
destabilization of intra-loop hydrogen bond networks in rAAV serotype 1 (rAAV1) via 
select amino acid deletions in VR1 increased transduction efficiency by orders of 
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magnitude in skeletal muscle following intramuscular injection. We further applied this 
strategy to numerous additional serotypes to create capsids harboring mutations 
designed to disrupt VR1 stability. These novel capsids specifically and efficiently target 
cardiac and skeletal muscle tissue following intravenous administration. This work is the 
first demonstration of which we are aware of a rational engineering strategy that can 
create muscle-targeted vectors in a conserved manner across serotypes. Our method 
expands the pool of reagents available to treat cardiac and musculoskeletal disease 
and offers an attractive pathway towards patient-personalized gene therapy. The ability 
to optimize numerous capsids using a single, easily accessible mutational strategy 
facilitates the pairing of a given serotype to a given patient based on preexisting 
variables such as neutralizing antibody titers, and removes the reliance on a single 
serotype for a given application.
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CHAPTER 1: INTRODUCTION1 
Gene therapy has the potential to not only cure genetic disorders, but to also 
facilitate the long-term non-invasive treatment of acquired and degenerative disease. 
Worldwide, there have been approximately 2100 gene therapy clinical trials to date 
(wiley.co.uk/genmed/clinical), of which 75 have made it to Phase III. Though trials 
utilizing rAAV represent just 5.5% of the whole, they have arguably produced the 
greatest clinical success. Translational studies conducted using rAAV-mediated gene 
therapy have culminated in the first regulatory approval of a gene therapy reagent for 
human use. Glybera employs an rAAV1 capsid to deliver a corrected form of the 
lipoprotein lipase gene (LPL) to patients suffering from lipoprotein lipase deficiency 
(LPLD) [1]. Despite success in the clinic, several obstacles remain that impede the 
expansion of rAAV into a widely usable vector. These include insufficiencies in 
transduction efficiency [2, 3], the promiscuity of vector biodistribution following 
intravenous administration [4], and the prevalence of neutralizing antibodies against the 
capsid within the population at large [5]. The work described herein identifies a novel 
structure-function relationship of a select region on the rAAV capsid surface, with the 
purpose of developing a new logical method of engineering the capsid to overcome 
1 Portions of this chapter previously appeared in an article in the journal Current Gene Therapy. The 
original citation is as follows:  Warischalk JK, et al., AAV’s anatomy: roadmap for optimizing vectors for 
translational success. Curr Gene Ther. 2010 Oct; 10(5): 319-40.   
1
2	  
these barriers. The following introduction will provide an in depth background into rAAV 
biology, and describe how this biology has molded the current clinical landscape of 
rAAV as a vector.  
1. Discovery and classification of AAV
AAV was discovered via electron microscopy as a contaminating factor of 
adenoviral preparations isolated from simian tissue stocks [6]. As AAV is small (~25 nm 
in diameter) and incapable of replicating on its own, early researchers found it to be a 
perplexing entity [7]. No evidence of disease could be attributed to the presence of AAV 
[8], leading it to be classified as “an extreme state of viral defectiveness [9].” It has also 
been classified as a dependovirus under the Parvoviridae family. Interest in AAV 
plateaued at this point in history, and was primarily characterized by many additional 
discoveries that AAV “contamination” of mammalian tissues was far more ubiquitous 
than previously appreciated [10-12]. In the 1970’s, the idea of using viruses as gene 
transfer vehicles in order to cure human disease began to take root in the scientific 
community [13, 14]. AAV’s lack of pathogenicity and inability to autonomously replicate 
made it an attractive candidate for this purpose. Following enticing proof-of-concept 
studies towards this end [15, 16], interest in AAV increased dramatically. Indeed, rAAV 
has become one of the most promising human gene therapy vectors of today [17]. To 
date, 13 distinct AAV serotypes have been identified [18-20], and more than 100 
additional clonal isolates have been found [21, 22]. Variants isolated from human 
tissues can be classified into 8 different clades based on functional and serologic 
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similarities imparted by the unique capsid protein sequence of each [23]. The incredible 
diversity of this viral species has enabled a wide foundation from which to build gene 
therapy vectors.    
 
2. Organization of the AAV virion 
  
 The AAV virion is relatively simple, consisting of a non-enveloped capsid and a 
single-stranded DNA genome. The capsid is comprised of 60 repeating protein 
monomers. The viral genome (Figure 1.1) is a linear 4.7 kb long molecule that is 
flanked on either end by T-shaped hairpin loops called inverted terminal repeats (ITRs). 
These ITRs serve as origins of replication for the viral DNA, as well as chromosomal 
integration elements [24, 25]. The genome encodes two genes – Rep and Cap – which 
give rise to eight proteins through alternative promoter start sites and splicing variants 
[26-28]. The Rep gene contains a single open reading frame (ORF) transcribed from 
two promoters, p5 and p19, to produce two overlapping families of replication proteins, 
denoted by molecular weight as Rep78, Rep68, Rep52 and Rep40. These non-
structural proteins are classified as SF3 helicases and participate in viral genome 
replication, transcriptional control, integration, and genome encapsidation [29-36]. The 
Cap gene is transcribed from a third promoter, p40, and contains two ORFs that encode 
the structural viral proteins (VPs) that comprise the capsid and the assembly-activating 
protein (AAP) that is required for capsid assembly [37, 38]. By way of differential start 
codons and alternative splicing, three different VPs (VP1, VP2, VP3) are transcribed 
[39-41]. The resultant proteins combine to form the capsid. The ITRs flanking the viral 
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genome are the only element required in cis to produce a mature virion [42]. Thus, if 
Rep and Cap are supplied in trans during viral production, any gene of interest that is of 
appropriate size (~4.7kb) can be cloned between the ITRs and packaged into the capsid 
[43]. This ease in the ability to produce recombinant AAV makes it readily adaptable as 
a gene therapy vector. Different naturally occurring AAV serotypes contain both diverse 
capsid amino acid sequences [44] and unique ITR structures [45]. For the purposes of 
standardization, rAAV gene therapy vectors are primarily pseudo-typed to include 
rAAV2 ITRs regardless of which capsid sequence is being utilized [46], such that the 
capsid alone will determine the behavior of different serotypes in vivo [47]. 
 
3. Structural organization of the AAV capsid 
  
 The AAV capsid is comprised of 60 repeating monomers, which come together to 
form a T = 1 icosahedron with an estimated diameter of 25nm and approximate 
molecular weight of 4 megadaltons. The capsid is predominantly comprised of VP3, 
which outnumbers both VP2 and VP1 by 10:1 in a mature virion, for an end result of 50 
copies of VP3, 5 copies of VP2 and 5 copies of VP1 per capsid [48]. All of the VPs 
contain the same ~530 amino acid long C-terminal sequence, while VP1 and VP2 have 
N-terminal extensions of ~200 and ~65 amino acids, respectively. Numbers are 
approximate based on variability between serotypes. The unique N-terminal regions of 
VP1 and VP2 contain phospholipase A2 domains and nuclear localization sequences 
that are utilized during intracellular trafficking of the virus [49, 50]. Crystal structures 
have been solved for the VP3 regions of the most commonly occurring AAV serotypes 
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(AAV1-AAV9), as well as for a handful of additional naturally occurring and laboratory-
derived variants [51-57]. The N-terminal extensions present in VP1 and VP2 are not 
amenable to crystallographic analysis, as they are tucked into the interior of the capsid 
in a non-symmetrical manner [58]. 
 In all serotypes characterized thus far, a jelly-roll β-barrel motif forms the bulk of 
VP3’s structure [59]. In the case of AAV, this motif is characterized by nine antiparallel 
β-sheets (Figure 1.2), interspersed with long loops that form much of the topology of 
the assembled capsid surface, and are named based on which β-sheets they connect 
(e.g., the AB loop, the BC loop, etc). In aligning the capsid protein sequence of various 
AAV serotypes, it is readily apparent that these loops also contain the majority of amino 
acid variability that occurs within this viral species. Therefore, select regions of these 
loops are also referred to as the “variable regions” of the capsid [60], of which there are 
9 (VR1-VR9). Predictably, it has been demonstrated that these VRs are the primary 
determinant behind the unique phenotypes observed for each serotype (e.g., receptor 
binding preferences, transduction efficiency, antigenicity).     
 The capsid surface is punctuated by certain hallmark features based on the 
symmetrical relationship between monomers (Figure 1.3). The 3-fold axis of symmetry, 
or trimer, forms a prominent spike on the capsid surface that has been shown to serve 
as a cell-surface receptor-binding region in various AAV serotypes [61-63]. The 5-fold 
axis of symmetry, or pentamer, forms a cylindrical structure called the 5-fold pore, which 
connects the interior and exterior environments of the capsid. It is believed that the viral 
genome is inserted into this pore as the final step during virion assembly [64]. The 2-fold 
axis of symmetry, or dimer, is characterized by a small depression that has been 
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interchangeably referred to as either the 2-fold dimple or 2-fold canyon. This region of 
the capsid contains the weakest inter-monomer interactions and is believed to 
participate in the uncoating of the capsid during transduction [65]. The work detailed in 
Chapters 2 and 3 of this dissertation focused on uncovering the structure-function 
relationship for VR1, aka Loop BC, which lies at the base of the 3-fold spike of the AAV 
capsid.      
 
4. Intracellular life cycle of rAAV 
 
The infectious life cycle of rAAV follows a distinct order of events, which includes: 
1.) attachment to the cell membrane via engagement of specific receptors and co-
receptors [66, 67]; 2.) receptor-mediated endocytosis [68]; 3.) endosomal trafficking and 
escape [69]; 4.) translocation to the nucleus through the nuclear pore complex [49]; 5.) 
uncoating of the capsid to deliver the viral genome [70]; 6.) conversion of the single-
stranded DNA viral genome into a double-stranded transcriptionally active form [71]; 7.) 
expression of Rep genes and subsequent replication of the viral genome [72], 
concomitant with 8.) expression of Cap genes and assembly of the capsid [37]; 9.) 
insertion of newly synthesized single-stranded viral genomes into empty capsids [73]; 
and, 10.) release of virions from the infected cell. Steps 7-10 of this process only occur 
in wild-type (non-recombinant) AAV infections, in the presence of either a helper virus 
[74-76] or select genotoxic agents [77], and therefore will not be discussed in detail in 
this dissertation (which focuses solely on the optimization of rAAV for human gene 
therapy purposes). Furthermore, the above life cycle represents what occurs during 
	   7	  
transduction with rAAV2, and select details may be different when examining other 
serotypes [78]. Following step 6 of the above pathway, the double-stranded viral 
genome exists either episomally within the nucleus or integrates into the host genome 
at a very low frequency [79]. The long-term persistence of the transgene coupled with 
the ability of the capsid to enter non-dividing cells is one of the chief features that make 
rAAV an attractive vector for gene therapy. It should be noted that while wild-type AAV 
has been found to only integrate into the host genome at the specific locus AAVS1 on 
human chromosome 19, rAAV appears to integrate in a more random and disbursed 
manner [80]. 
The variability amongst capsid protein sequences of different AAV serotypes is 
believed to be responsible for the unique phenotypes observed for each. For instance, 
AAV demonstrates an exceptionally wide range of tissue tropism [4], which is believed 
to be primarily dictated by variability in capsid:receptor interactions. rAAV2, which 
predominantly transduces the liver following intravenous injection into mice [4], has 
been found to interact with heparan sulfate proteoglycans (HSPGs) as a means of 
attaching to the cell surface [67]. A host of different co-receptors (e.g., α5β1 integrin 
[66], c-Met [81], fibroblast growth factor receptor 1 [82]) then engage the capsid to 
facilitate endocytosis. rAAV9, which strongly transduces the heart [4], engages terminal 
galactose moieties to engage with the cell surface [83]. It is notable that the majority of 
capsid:receptor interactions that have been defined to date are extrapolated from cell 
culture experiments. In vivo, there appears to be a discrepancy between what exact 
receptors are necessary for rAAV to transduce various tissues, as there are several 
instances in which the abrogation (via mutagenesis) of the ability of the rAAV capsid to 
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interact with a given receptor actually markedly enhances in vivo transduction efficiency 
[63, 84-87]. Moving forward, it will be necessary to resolve these discrepancies to fully 
appreciate how rAAV functions in a physiological environment. Despite these 
uncertainties, the understanding provided by this model has enabled great strides in the 
ability to optimize the virion for translational studies. 
Numerous steps along the above-detailed pathway can potentially be rate limiting 
to the successful transduction of a given tissue by rAAV. For instance, the inability to 
interact with the cell-surface will obviously prevent transduction from occurring. The 
ability of the capsid to escape the endosome and enter the cytoplasm/translocate to the 
nucleus is triggered by late endosomal pH-dependent (acidic) changes that trigger a 
conformational transformation of the capsid that exposes the phospholipase A2 
domains and nuclear localization sequences that comprise the VP1 and VP2 N-terminal 
regions [69]. This process can also pose a significant rate-limiting step towards 
successful transduction. Furthermore, even following successful escape of rAAV from 
the endosome, a perinuclear pool of capsids often accumulates in close proximity to the 
microtubule-organizing center [49, 88]. Such populations have been shown to persist for 
years following initial cell entry of virus [3], and clearly reduce overall transduction 
potential. Even for capsids that enter the nucleus successfully there is still the issue of 
capsid uncoating to deliver the viral transgene, which has been shown to proceed at 
very different rates according to which serotype is being examined [89]. Each of these 
steps along the transduction pathway is governed by the protein sequence of the 
capsid, and each offers an opportunity to improve rAAV vectors for the clinic.  
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5. Physiological life cycle of AAV 
 
rAAV transduction efficiency in vivo is obviously not simply determined by 
completion of the intracellular life cycle described above. Regardless of the route of 
entry into the body, rAAV immediately encounters a vast physiological milieu that must 
be navigated prior to reaching the cell surface. Intravenously delivered virus encounters 
numerous proteins and cells within the bloodstream that effect transduction efficiency 
long before capsids reach the surface of a target cell. A major obstacle to transduction 
is the presence of neutralizing antibodies against the capsid [5]. AAV infection is near 
ubiquitous in the human population, which is demonstrated by the large percentage of 
people that harbor neutralizing antibodies against at least one serotype (and often many 
more). This results in the clearance of capsids before they can reach their intended 
therapeutic target [90], and presents a serious hurdle towards successful gene therapy 
via systemic vector administration [91]. rAAV vectors are also lost from the bloodstream 
via endocytosis by circulating macrophages and Kupffer cells [92]. Interactions between 
the capsid and additional serum proteins, such as galectin 3 binding protein [93] and c-
reactive protein [94], can also impact in vivo transduction efficiency. Finally, different 
serotypes demonstrate varying abilities to transcytose the vasculature to reach target 
cells [95]. Obstacles imposed by the in vivo environment are not limited to intravenously 
administered capsids. Capsids introduced into the airway, for instance, must navigate 
through mucosa rich in molecules that can compete with the target cell surface for 
receptor binding regions of the capsid (e.g., sialic acid) and thus inhibit capsid:cell 
interactions [96]. Even vectors directly injected into a target organ may suffer from an 
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inability to migrate past the site of injection [97], resulting in punctate gene correction 
that is insufficient to correct a disease phenotype. Achieving robust tissue-specific 
transgene expression in vivo is clearly a non-trivial facet of rAAV-mediated gene 
therapy.    
 
  6. Clinical trials utilizing rAAV 
 
Despite the obstacles to transduction efficiency that are imposed by the 
intracellular and physiological environment, rAAV vectors have still exhibited marked 
clinical success in both safety and efficacy [98]. Of the ~120 worldwide clinical trials 
conducted using rAAV, about 10% have made it through Phase III 
(wiley.co.uk/genmed/clinical). These trials have focused on many areas of disease, 
including monogenic diseases, cancer, cardiovascular disease, neurological diseases, 
infectious diseases, and ocular diseases [17]. Early clinical trials utilized rAAV2 for gene 
delivery, as rAAV2 is the most well characterized serotype to date, having been the first 
serotype to be successfully cloned for in vitro viral production [99]. However, rAAV2 is 
not an efficient transducer in the in vivo environment [4], and the majority of clinical trial 
success was not achieved until alternative serotypes were investigated [17, 98]. For 
example, rAAV1 has now become the standard for applications requiring transgene 
expression in muscle tissue [3] and rAAV8 for applications requiring transgene 
expression in the liver [100]. The continual isolation of new rAAV serotypes and variants 
provides an ever-growing foundation of reagents to select from that will certainly 
enhance translational success moving forward.     
	   11	  
Three general approaches of therapeutic gene delivery have been used in the 
clinical setting. The first is direct injection of rAAV into the organ afflicted by disease. 
Perhaps the most successful demonstration of this method is the use of either 
subretinal or intravitreal injections to deliver rAAV into the eye. For example, striking 
corrections of disease phenotype were observed in three independent phase I clinical 
trials employing an rAAV-delivered copy of the rpe65 gene to patients suffering from 
Leber’s congenital amaurosis (LCA), a congenital form of blindness [101-103]. In one 
follow up study, visual acuity was restored in patients administered a single dose of 
vector [104], with safety and efficacy persisting for over 4 years as of the time of this 
writing. The success of these studies was due predominantly to the retina being the 
target of the gene therapy. The retina is small, easily accessible, and immune-
privileged, which allows for the direct application of a relatively low dose of virus without 
fears of an immune response inhibiting the virus from reaching target cells or degrading 
transduced cells over time. Disorders of the heart [105], skeletal muscle [106], and 
central nervous system [107] have also been treated via direct injection with varying 
degrees of success. 
The next method of administering rAAV gene therapy is the utilization of a target 
organ to act as an intermediary in supplying the body with a required secreted protein. 
In this case, the organ being targeted for transduction is not necessarily diseased. For 
example, skeletal muscle has been utilized to secrete therapeutic proteins into the 
bloodstream, such as alpha-1 antitrypsin (AAT) for patients suffering AAT deficiency [3], 
or Factor IX for patients suffering from hemophilia B [108]. Glybera, the first gene 
therapy reagent approved for human use in the Western world [109], functions to 
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ameliorate the disease burden of LPLD by way of a series of whole body intramuscular 
injections that lead to the secretion of LPL into the bloodstream [110]. In each of the 
above examples, the principal limiting factor towards disease correction has been the 
difficulty in acquiring sufficient levels of transgene expression/secretion from the muscle 
to achieve therapeutic effect. Indeed, even in the case of Glybera, patients require up to 
60 separate injections of extremely high doses of vector to achieve clinical correction 
[111], making it the world’s most expensive drug at the time of this writing (~$1.4 million 
USD per treatment). These trials have primarily utilized rAAV1 as the serotype of choice 
for gene delivery [3, 110], as rAAV1 has the most favorable skeletal muscle 
transduction phenotype [4]. In Chapter 2 of this work we describe a novel method of 
rationally engineering the rAAV1 capsid in order to improve musculoskeletal transgene 
expression and demonstrate an enhancement of transduction efficiency by up to 137-
fold following intramuscular injection of vector. We further demonstrate the utility of our 
approach in improving the secretion of therapeutic proteins into the bloodstream.  
 The final method that has been employed for therapeutic gene delivery is the 
targeting of desired organs following intravenous administration of vector. Efforts 
towards this method are still in their infancy, as all naturally occurring serotypes that 
have been isolated to date preferentially transduce the liver following intravenous 
injection [4]. Thus, the only clinical success using systemic administration thus far has 
been for applications in which the desired target of rAAV transduction is hepatic tissue. 
The most promising example of such a strategy has been in the genetic correction of 
hemophilia B [100, 112]. Through a single peripheral vein injection of an rAAV8 capsid 
packaging the human factor IX (FIX) gene, an entire cohort of patients (six patients) 
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were able to either discontinue or significantly delay the interval of time in between 
prophylactic injections of recombinant FIX protein and remain free of spontaneous 
bleeding episodes. Correction has been maintained for several years as of the time of 
this writing. To further expand the repertoire of disorders that rAAV-based gene therapy 
can be used to treat following systemic administration, it will be necessary to develop 
methods to control vector biodistribution. In Chapter 3 of this work we describe a novel 
protein engineering method that can be applied to the capsid in order to improve tissue 
targeting to either cardiac/skeletal muscle or the liver following intravenous injection. We 
demonstrate that this method is applicable to numerous serotypes, greatly expanding 
the current pool of rAAV reagents available for translational use. 
  
7. Exogenous methods of improving rAAV as a gene therapy vector 
 
One broad method of overcoming inefficiencies in rAAV tissue targeting and 
transduction is the introduction of exogenous agents during rAAV delivery to the host. 
Such agents have included modifications of the virion, and/or the coadministration of 
pharmacologic agents and rAAV [17]. Encoating the capsid with various polymers has 
been one method of shielding rAAV’s natural tissue biodistribution patterns while 
simultaneously providing a substrate on which to introduce ligands to target tissues-of-
interest [113-116]. This method has also been used to camouflage the capsid from 
neutralizing antibodies [117]. However, at the time of this writing these methods have 
not proceeded beyond pre-clinical proof-of-principle experiments. Preliminary studies 
have also examined the use of pharmaceutical agents to improve rAAV transduction in 
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vivo. The most clinically relevant example of such is the transient use of 
immunosuppressing agents at various time points surrounding vector administration 
[118].  A controversial area of research contends that rAAV-mediated gene transfer into 
certain types of tissue results in the expansion of capsid-specific T cells that are 
capable of destroying cells that have been transduced by vector [119] to cause a loss of 
transgene product. Several immunosuppressive regimes have been evaluated to 
overcome this, and transient immunosuppression is now commonly employed in clinical 
rAAV administration to protect transgene expression [120]. Transgene expression can 
also be enhanced through several pharmaceuticals, of which proteasome inhibitors are 
a notable example [121]. Again, many of these efforts remain as pre-clinical proof-of-
principle studies, as endogenous modifications of the rAAV virion are currently proving 
to be safer and more effective means of enhancing transduction efficiency [17].      
 
8. Endogenous methods of improving rAAV as a gene therapy vector 
  
New generations of “designer vectors” are being developed to ease the burden of 
virtually all of the above listed obstructions towards gene delivery using rAAV. There 
have been two general approaches towards creating such vectors: 1.) viral transgene 
modification using regulatory elements such as tissue-specific promoters [122] or micro 
RNAs [123]; 2.) viral capsid modification via methods such as directed evolution [124] or 
manipulation of receptor binding footprints [85]. Transcriptional targeting of rAAV has 
proven to be an effective means of restraining transgene expression to specific tissues. 
For example, the tumor-specific hTERT promoter has been used to drive rAAV 
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transgene expression in cancer cells without generating measurable expression in 
normal cells [125]; using this promoter to drive the expression of cell-lethal transgenes 
such as TRAIL and IFN-β has demonstrated potent anti-tumor effects in mouse cancer 
models while sparing normal cells [126, 127]. A promoter derived from the human 
rhodopsin kinase gene was incorporated into the rAAV transgene in order to limit 
transgene expression patterns in the eye. This promoter is active in both rods and 
cones simultaneously, which allowed for the expression of the therapeutic transgene 
aipl1 at near endogenous levels within these two cells types, with no aipl1 expression 
found in other regions of the eye [128]. Similar refinements to transgene expression can 
be attained through incorporating regulatory RNA elements into the virion [123]. While 
transcriptional regulation strategies are proving to be an effective means of honing 
transgene expression to desired tissue types, it is unlikely that the field will evolve to 
rely solely on these methods of control. Such strategies do not prevent capsid 
sequestration in undesired cell types, which impacts how much vector must be 
delivered to the patient. However, combining transcriptional control elements with an 
optimized capsid could create an attractive platform for highly specific tissue targeting. 
Modifying the capsid protein has emerged as a prominent strategy for optimizing 
rAAV vectors [17]. Two approaches have been used towards this end: the 
indiscriminant generation of novel capsids through directed evolution and random 
mutagenesis, and the rational design of capsids to enhance specific aspects of 
transduction efficiency and/or tissue targeting. Directed evolution is a combinatorial, 
high-throughput feat of molecular biology that employs a library created from randomly 
shuffled fragments of capsid DNA garnered from many different inputs (naturally 
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occurring serotypes, various capsid mutants, etc).  As the primary regions of amino acid 
variability in the rAAV capsid protein correspond to labile surface loops (see Chapter 
1.3, above) and not to the β-sheets that form the core structural stability of the capsid, 
the Cap gene is highly amenable to such efforts and can easily recombine to include 
many different DNA variations without impacting the ability to create intact virions [124]. 
The capsid library can then be “evolved” through iterative rounds of infection in cell 
culture or in animal models (a process known as in vivo biopanning) to create novel 
capsids that can transduce virtually any cell type [129]. Variations of this theme include 
subjecting the capsid of a single serotype to random PCR-based mutagenesis and then 
evaluating the phenotype of resulting mutants [130], and the creation of a randomly 
generated pool of potential targeting ligands that can be subsequently incorporated into 
the capsid at pre-selected locations [131]. These methods have been very successful in 
creating capsids with the ability to target chosen tissues. The primary disadvantages of 
directed evolution include the inability to detarget transduction from unintended tissues, 
and the inability to biologically interpret resultant capsids (generated capsids often 
contain such a breadth of diverse elements that understanding which are necessary to 
produce a given phenotype becomes exceedingly difficult). 
Rational design of the rAAV capsid has been made accessible by the availability 
of crystal structural data for numerous serotypes. One approach made available through 
such data is the manipulation of receptor binding regions of the capsid. For example, 
five amino acids in an rAAV2 capsid surface loop were identified to serve as a binding 
site for HSPGs. rAAV2 is a poor transducer in vivo and transgene expression is 
predominantly found in the liver. It was hypothesized that replacing these five amino 
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acids with those that occupy the equivalent position in rAAV8 would not only interrupt 
the heparin binding capabilities of rAAV2, but would also confer the strong systemic 
transduction of rAAV8 into an rAAV2 backbone. The new construct, rAAV2i8, 
demonstrated a 40-fold decrease in liver transduction concurrent with high transgene 
expression levels found in samples of muscle tissue taken from many regions of the 
body [85]. Likewise, disruption of the galactose binding region of the rAAV9 capsid 
altered vector biodistribution into a more systemically distributed, liver-detargeted 
phenotype [87]. Though these results demonstrate that the reengineering of receptor 
binding footprints on the capsid surface can enhance the virion for translational 
applications, this method is unfortunately confined to serotypes for which receptor 
binding regions on the capsid surface are known.  
Another approach towards rational capsid design has been the identification and 
mutation of select surface-exposed tyrosine residues in order to enhance transduction 
efficiency. It was found that select tyrosine residues become phosphorylated once the 
capsid enters the intracellular environment, and as a result capsids become tagged for 
ubiquitination and subsequent proteasomal degradation [132]. Capsids that had such 
tyrosine residues mutated to phenyalanine could avoid clearance and thus had a 
greater probability of translocating to the nucleus and delivering transgenes. This 
strategy can enhance transduction efficiency by up to 30-fold in vivo, depending upon 
the tissue type being studied. 
  A third rational design approach took advantage of the diversity amongst the 
capsid protein sequences of different rAAV serotypes in order to develop a chimeric 
capsid enhanced for skeletal muscle application [133]. The VRs of rAAV2 were 
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compared with those from serotypes more efficient at transducing muscle, such as 
rAAV1. This led to the isolation of five amino acids from rAAV1 based on their 
hypothesized contribution to rAAV1’s efficiency in muscle. These amino acids were then 
engrafted onto rAAV2 to create rAAV2.5. Following injection into skeletal muscle, 
rAAV2.5 significantly enhanced transduction efficiency relative to rAAV2, and the 
promise of these results led rAAV2.5 to become the first laboratory-derived capsid to 
enter a clinical trial [133]. However, the decision to improve rAAV2 was based on it 
being the only serotype approved for clinical trial use at the time. Though rAAV2.5 was 
an improvement over rAAV2, it could not achieve the levels of transgene expression 
that resulted from transduction with the more muscle-tropic serotypes such as rAAV1. 
rAAV1 has since become the top choice for clinical applications targeting the 
musculoskeletal system, being used in 67% of muscle-based clinical trials overall and in 
86% over the past 5 years [134]. The primary objective of this dissertation was to 
understand why the amino acids originally isolated from the VR1 region of rAAV1 to 
create rAAV2.5 are so influential to transduction efficiency in muscle tissue. In 
answering this question we defined precise structural elements that govern rAAV1’s 
transduction efficiency. We then applied this information to additional serotypes to 
create a panel of modified capsids that not only demonstrate order of magnitude 
increases in transduction efficiency relative to parental capsids, but also target cardiac 
and skeletal muscle tissue with high specificity following intravenous injection. These 
novel capsids will help overcome many of the obstacles to clinical success that are 
discussed throughout the introduction, each of which will be highlighted in the preceding 
chapters.  
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Figure 1.1. Organization of the AAV genome. The AAV genome contains two 
ORFs that translate into eight different proteins by way of alternate promoters and splice 
sites. Proteins include four replication proteins named for molecular weight as Rep78, 
Rep68, Rep52, and Rep40, the three structural proteins that make up the capsid named 
as VP1, VP2, and VP3, and the capsid assembly protein, AAP. The Rep and Cap genes 
are flanked by ITRs. When making recombinant AAV, the Rep and Cap genes are 
removed and a gene-of-interest is cloned in between the ITRs, which are the only cis 
element required to encapsidate the genome. Typical genes-of-interest include either 
therapeutic transgenes or reporter genes (e.g., luciferase, GFP).  
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Figure 1.2. Organization of the AAV monomer. Cartoon representation of 
PyMol image of an AAV2 monomer. Cartoon (not to scale) depicts organization of the β-
barrel core, including names of β-sheets (A-I) and interspersed loops (loop AB, etc). 
Variable regions of the capsid are denoted by Roman numerals I-IX. 
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Figure 1.3. Organization of the AAV capsid. PyMol representation of the AAV2 
capsid. The capsid is comprised of 60 repeating monomers that assemble into a T=1 
icosahedron. The three axes of icosahedral symmetry are shown. They are also 
referred to as the trimer (3-fold), dimer (2-fold), and pentamer (5-fold).
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    CHAPTER II: 
UTILIZING STRUCTURAL MODELING AND MOLECULAR DISSECTION OF 
AAV CAPSID ARCHITECTURE TO IDENTIFY MOTIFS THAT ENHANCE  
SKELETAL MUSCLE TRANSDUCTION 
 
 
Summary 
Recombinant adeno-associated viral (rAAV) gene therapy has proven safe in 
clinical trials, but sub-therapeutic transduction remains a challenge. To overcome this, 
serotypes efficacious at transducing given tissues have been utilized in respective 
clinical studies (e.g., rAAV1 for muscle disorders, rAAV8 for liver). Recently, we 
demonstrated the utility of developing chimeric rAAV2 capsids to improve outcome in 
Duchenne muscular dystrophy. To extend these efforts, we employed molecular 
modeling, genetic, and biochemical analyses of rAAV1 to identify components that 
augment transduction. Mutating a single capsid residue at position 265 enhanced 
musculoskeletal transduction 137-fold. Intriguingly, the highly homologous rAAV6 
required additional mutation to enhance transduction. A marker rescue approach 
identified that rAAV6 heparin binding ability counteracted effectiveness of 265 mutation. 
Converting rAAV6 to a heparin-null phenotype overcame this. Heparin competition and 
affinity chromatography revealed that the heparin binding site and position 265 work 
allosterically to modulate receptor binding and transduction efficiency. This held true for 
rAAV2, suggesting a universal interplay between these protein motifs. Mutation and
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structural modeling of residues flanking 265 uncovered that regional destabilization 
drives transduction enhancement rather than amino acid identity, per se. Established 
herein is a strategy to improve rAAV reagents for clinical testing. 
Introduction  
Various serotypes of recombinant adeno-associated virus (rAAV) are currently 
being utilized in clinical trials (e.g., rAAV1 for lipoprotein lipase deficiency[110], rAAV2 
for Leber’s Congenital Amaurosis[135], rAAV8 for hemophilia[100]). Of these, rAAV1 is 
considered the best for intramuscular (i.m.) delivery, whether treating muscle disorders 
directly (e.g., muscular dystrophy[136]) or for conditions that can benefit from the 
secretion of a therapeutic protein into the bloodstream (e.g., α-1 antitrypsin (AAT) 
deficiency[137]). A major limitation of this approach has been sub-therapeutic levels of 
transgene expression, despite the administration of high doses of rAAV. For example, 
while results from rAAV-AAT clinical trials demonstrate dose dependent increases in 
serum levels of AAT following i.m. injection, in high dose cohorts only ~3% of target 
AAT expression was achieved[2, 3]. As this cohort required 100 i.m. injections of 
1.35mL each, increasing the dose to the degree necessary for disease correction may 
not be feasible. Similar observations have been documented for the recently approved 
rAAV1-based pharmaceutical, Glybera[110]. For rAAV gene augmentation therapy to 
become a practical choice in cases such as these, improving transduction efficiency in 
muscle tissue is essential.  
Efforts towards increasing transgene expression can be divided into endogenous 
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approaches, wherein the rAAV capsid and transgene themselves are modified to 
enhance transduction, and/or exogenous approaches, wherein supplementary 
therapeutics are delivered concurrent to rAAV administration[17]. While exogenous 
approaches such as immune suppression have improved transduction[138], the process 
of integrating new discoveries of rAAV biology into clinical trial design has been the 
most successful tactic. This is best illustrated with the development of numerous 
naturally occurring AAV serotypes and their preferential tissue transduction profiles[98]. 
This enables correct pairing of AAV serotype to target organ (e.g., clinical trials utilizing 
i.m. delivery of rAAV became demonstrably more successful when rAAV1 was 
employed[2, 3, 137], as opposed to the historically utilized rAAV2[139, 140]). 
Additionally, serotype-comparative biological and structural analyses have facilitated 
directed evolution and rational engineering of rAAV, leading to the development of next 
generation translational vectors[17, 98].  
The capsid structure of most common rAAV serotypes has been resolved[51-54, 
57, 60, 141]. Each contains 60 repeating monomers, comprised of a conserved β-barrel 
core interspersed with large loops that form the topology of the capsid surface. By 
comparing the structures of rAAV2 and rAAV4, the least homologous serotypes, a total 
of nine variable regions (VRs; VR1 to VR9) were defined[60]. The amino acid content of 
the VRs contributes distinct phenotypes to each serotype, such as receptor binding, 
antigenic reactivity and transduction efficiency. Comparing the VRs of rAAV2 (the 
prototypical rAAV) with more efficient muscle transducers, such as rAAV1, led to the 
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first engineered rAAV capsid to enter clinical trial[133]. rAAV2.5 consists of an rAAV2 
capsid engrafted with five amino acids from rAAV1, isolated for their contribution to 
rAAV1’s efficiency in muscle. Follow-up studies revealed that only a single amino acid 
change was needed to markedly enhance rAAV2 efficiency in muscle, namely, insertion 
of various amino acids following position 264, thereby creating a de novo position 
265[142]. Continued pre-clinical studies have suggested that the translatability of rAAV2 
is limited by the superior efficiency of serotypes such as rAAV1 and rAAV6[98], as well 
as by the high prevalence of rAAV2 neutralizing antibodies within the population[143]. 
These “next generation” serotypes have been augmented further for efficient 
transduction by modulation of surface amino acids on the capsid backbone[17, 98].  
As rAAV1 has become the top choice for musculoskeletal application, being used 
in 67% of i.m.-based clinical trials overall and 86% in the past 5 years[105, 144-149], 
improving rAAV1 efficiency is timely to clinical translation. This study dissected rAAV1 
capsid architecture to develop an engineering strategy designed to improve muscle 
transduction. Contrary to rAAV2 265 insertion mutants[142], the deletion of position 265 
from the rAAV1 capsid provided the highest level of enhancement for both transgene 
delivery and expression in muscle tissue. Furthermore, through homology modeling and 
mutational analysis, two regions of the capsid were identified that appear to work 
together allosterically to control transduction efficiency in rAAV6 and rAAV2. This 
discovery allowed for rational mutation of these additional serotypes in order to enhance 
transduction efficiency by at least an order of magnitude in each case. Furthermore, 
expression of the clinical AAT transgene in our chimeric rAAV serotypes increased 
	   26	  
expression by up to 12.5-fold over parental rAAV1, supporting further testing of these 
constructs in clinical trials. This study validates a rational design approach using 
structural modeling and molecular dissection of the rAAV capsid for improved delivery 
reagents better suited for translational studies.  
 
Results  
Mutation of position 265 on the rAAV1 capsid enhances transduction of skeletal muscle  
As insertions of aspartic acid, glutamic acid or phenylalanine following position 
264 in the rAAV2 capsid (creating a de novo position 265) enhanced skeletal muscle 
transduction by an order of magnitude[142], we hypothesized that substitution of the 
naturally present threonine at position 265 in rAAV1 with D, E, or F would enhance 
skeletal muscle transduction in this serotype (rAAV1 is one amino acid longer than 
rAAV2 in this capsid loop). As a control, T265 was deleted from rAAV1, so as to 
resemble unmodified rAAV2. rAAV1, rAAV1/T265D, rAAV1/T265E, rAAV1/T265F and 
rAAV1/T265del capsids packaging the chicken β-actin promoter driven firefly luciferase 
(CBA-luc) transgene were injected into murine gastrocnemius (GC) muscle at a dose of 
1e10 viral genomes (vg). Live-animal bioluminescent imaging was performed 7 days 
post injection (dpi) in order to quantify transgene expression via measurement of 
emitted light (Figure 2.1A). rAAV1/T265D, rAAV1/T265E and rAAV1/T265F enhanced 
transgene expression relative to rAAV1 by 28-, 34- and 36-fold, respectively, supporting 
our previous analysis of the rAAV2 capsid backbone[142]. Surprisingly, rAAV1/T265del 
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enhanced transduction by approximately 200-fold over rAAV1. In an effort to better 
understand these phenomena, the 265 deletion mutant was used in the majority of 
remaining analyses within this study.  
To confirm that the image quantification method used to generate the above data 
was an accurate representation of transgene expression levels within injected muscle 
tissue, injected GCs were removed, homogenized/lysed and ex vivo luciferase assay 
performed on tissue lysate. In this assay, transduction efficiency with rAAV1/T265del 
was enhanced by 137-fold over rAAV1, when normalized for relative light units emitted 
per mg of tissue analyzed (Figure 2.1B). Increased rAAV1/T265del reporter gene 
expression correlated with enhanced transgene delivery to muscle: 14.5-fold more viral 
genome copies were detected per muscle cell relative to rAAV1 by quantitative real-time 
PCR (qPCR) analysis (Figure 2.1C). All results were confirmed in multiple experiments 
using independent preparations of vectors purified by several methods (e.g., density 
ultracentrifugation, affinity chromatography) to ensure that measured effects were not 
specific to batch or purification method.  
To ensure an appropriate time point was examined, a time course of rAAV1 and 
rAAV1/ T265del transgene expression was performed, with measurements collected at 
7, 14, 21 and 42 dpi (Figure 2.1D). Expression kinetics appeared the same, with robust 
expression observed at 7dpi, increasing by 7.5-fold between days 7 and 42 following 
injection of rAAV1 and by 12-fold during same time period following injection of 
rAAV1/T265del. At all time points, rAAV1/T265del outperformed rAAV1 by 
approximately two orders of magnitude (100-fold at day 7, 176-fold at day 14, 81-fold at 
day 21, and 159-fold at day 42). Taken together, these data demonstrate that deletion 
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of amino acid 265 in the rAAV1 capsid backbone is a highly effective strategy to 
enhance both transgene delivery and expression in skeletal muscle tissue. More 
importantly, this enhancement is maintained over a sustained period of time supporting 
our observation of increased vector genome copy numbers as documented by qPCR 
analysis.  
 
Distal residues work in conjunction with 265 to modulate transduction efficiency  
rAAV6 is considered another top candidate for musculoskeletal gene therapy 
applications[98], and is the serotype with the highest capsid sequence homology 
(99.2%) to rAAV1[150]. To determine whether the enhanced transduction phenotype 
obtained by the deletion of position 265 in the rAAV1 capsid would be conserved in the 
context of rAAV6, rAAV6 and rAAV6/T265del capsids packaging CBA-luc were 
generated. Seven days following injection of each into murine GC at a dose of 1e10vg, 
transgene expression was quantified. Intriguingly, the transgene expression following 
injection of rAAV6/T265del was only 82% of that measured when using rAAV6 (Figure 
2.2A). This was surprising considering the dramatic effects on transduction that deletion 
of position 265 produced in rAAV1, and that of the only 6 amino acids by which rAAV1 
and rAAV6 differ[150], none are located within sufficient spatial proximity to position 265 
to form direct interactions. Any residue that differs between rAAV1 and rAAV6 is located 
at least 22Å away from position 265. In order to form direct interactions such as 
hydrogen bonding, residues must be within ~3Å of each other. Despite this, there are 
conformational differences within the structure of rAAV1 and rAAV6 around position 265 
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(Figure 2.2B), as visualized by alignment of available crystallographic data for each[54, 
141]. 
To resolve which residues within the rAAV6 capsid might inhibit the effectiveness 
that deleting position 265 has on enhancing transduction efficiency a version of marker 
rescue experiment was employed, wherein the rAAV6 capsid was mutated at each 
residue that differs between rAAV1 and rAAV6 to the amino acid present in rAAV1, in 
conjunction with deletion of 265. Mutants were designated rAAV6.1 (rAAV6 with the first 
non-conserved residue (F129L) mutated to the equivalent amino acid in rAAV1), 
rAAV6.2 (D418E), rAAV6.3 (K531E), rAAV6.4 (L584F), rAAV6.5 (V598A) and rAAV6.6 
(H642N), respectively. The majority of changes to the rAAV6 capsid produced minimal 
change to transduction (Figure 2.2C). Transgene expression decreased by ≤2-fold with 
constructs rAAV6.1, rAAV6.1/T265del, rAAV6.2, rAAV6.2/T265del and rAAV6.3, 
respectively. Transgene expression was increased by approximately 2-fold in both 
rAAV6.4 and rAAV6.4/T265del. Mutations at position 598 and 642 (rAAV6.5 and 
rAAV6.6) reduced transgene expression relative to rAAV6 more dramatically than other 
mutations, decreasing it by 3.4- and 13.1-fold, respectively. Deletion of position 265 in 
conjunction with rAAV6.5 and rAAV6.6 produced little change to the performance of 
these constructs, decreasing transgene expression by 4.8- and 8.7-fold in 
rAAV6.4/T265del and rAAV6.5/T265del, respectively. Strikingly, only a single amino 
acid change, at position 531 (rAAV6.3), was required to rescue the 265 phenotype 
observed with rAAV1, with rAAV6.3/T265del enhancing transduction efficiency by 23-
fold relative to rAAV6 (Figure 2.2C).  
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The spatial relationship between residues 531 and 265 was examined in the 
context of the rAAV6 crystal structure[54] (Figure 2.3, A-D). Amino acids 265 and 531 
are not close enough to form direct interactions in any of the icosahedral axes of 
symmetry. In the 2-fold axis, positions 265 and 531 are ~26.7Å apart, whereas in the 5-
fold axis, they are ~42.6Å apart. However, in the 3-fold axis of symmetry, despite being 
located ~22.8Å apart, both residues are surface-exposed in the same plane (Figure 
2.3B). Residue 531 sits at the base of each 3-fold “spike” and 265 sits in a slight 
protrusion between spikes. Taken together, at this point in time, the above data 
suggests that the most likely context in which positions 265 and 531 may together 
modulate transduction efficiency is through the protrusions forming the 3-fold axis of 
symmetry.  
 
Capsid heparin binding ability affects the 265 phenotype, and vice-versa  
rAAV1 and rAAV6 both engage N-linked sialic acid as a primary receptor[151]; 
however, rAAV6 also binds to heparan sulfate moieties. Previously, our results have 
shown that K531 is the sole residue required for rAAV6 to interact with heparan 
sulfate[150]. K531 is also the sole residue required to rescue the 265 deletion 
phenotype observed in rAAV1. To further explore the functional relationship between 
capsid heparin binding and the enhanced transduction resulting from mutation of 
position 265 we examined rAAV2, the prototypical serotype known to utilize heparan 
sulfate proteoglycans as primary receptors for infection[67]. rAAV2 was mutated at 
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position 585 (a mutation known to attenuate rAAV2 heparin binding[63, 152]) in 
conjunction with insertion of aspartic acid to create a de novo position 265 as previously 
described[142]. rAAV2, rAAV2/265D, rAAV2/K585E and rAAV2/265D,K585E were 
injected into murine GC at a dose of 1e10vg. In agreement with previous reports, 
ablation of heparin binding enhanced rAAV2 transduction of skeletal muscle[63, 85]. 
However, concomitant mutation of position 265 and elimination of heparin binding ability 
produced the strongest enhancement of transduction efficiency (Figure 2.4A), 
increasing transduction by 96-fold over rAAV2 and 7-fold over rAAV2/265D and in 
agreement with above results observed for rAAV6 (Figure 2.2C). It is notable that 
residue 531 was mutated to ablate heparin binding in rAAV6 and residue 585 was 
mutated to ablate heparin binding in rAAV2. Though residues 531 and 585 are not close 
to each other in linear sequence, they both fall within an overlapping basic patch on the 
capsid surface that is the footprint for heparin binding (Figure 2.4B). To resolve whether 
direct inhibition of heparin binding enhances transduction of 265 mutants, heparin 
competition was performed prior to injection of 265 mutant constructs into mice. rAAV2 
binds heparin with stronger affinity than rAAV6, and is the only serotype historically 
shown to have effective diminution of transduction following incubation in a heparan 
sulfate solution[153], so this question was examined in the context of rAAV2. rAAV2 and 
rAAV2/265D capsids were incubated in either a saline solution or a 250µg/mL heparan 
sulfate solution overnight. rAAV1 was included as a control. Viruses were injected into 
murine GC at a dose of 1e10vg, and mice were imaged at 7 dpi. Incubation with 
heparan sulfate reduced transduction efficiency by approximately 3-fold in both rAAV2 
and rAAV2/265D and had virtually no effect on rAAV1, reducing transduction by 0.3-fold 
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(Figure 2.4C). These results suggest that the need to ablate heparan sulfate binding in 
order for mutation of position 265 to be effective at enhancing transduction is due to 
structural change within the capsid and not inhibition of heparin binding, per se.  
Heparin affinity chromatography verified that all rAAV2 and rAAV6 capsid 
mutations made to decrease heparin binding performed as expected (Figure  2.5, A-D). 
Relevant constructs were incubated with heparin-conjugated agarose and eluted with 
an increasing NaCl gradient. Interestingly, in capsids with position 265 mutated, heparin 
binding was attenuated relative to parental capsids. For example, 20% more 
rAAV2/265D than rAAV2 eluted during the first wash step following column loading of 
virus. Similarly, 20% less rAAV2/265D eluted in the 300mM NaCl fraction than did 
rAAV2. Likewise, 37% more rAAV6/T265del eluted during column washing than rAAV6, 
while 25% less rAAV6/ T265del eluted at the 200mM NaCl wash than did rAAV6, 
supporting the hypothesis of interplay between these two protein motifs (elution of 
rAAV6 during a less stringent wash fraction than rAAV2 agrees with previous work[150, 
153]). While rAAV2/K585E attenuated rAAV2 heparin binding, rAAV2/265D,K585E 
furthered this effect. 75% of rAAV2/ K585E and 96.5% of rAAV2/265D,K585E was 
eluted during initial wash steps. 10% less rAAV2/265D,K585E than rAAV2/K585E was 
eluted at 200mM NaCl. Combined with the data presented in Figures 2.3 and 2.4, 
these results add evidence that changes to the capsid region harboring position 265 
affect the structural conformation of that region harboring the heparin binding site, and 
vice-versa.  
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Multiple disruptions to VR1 structure enhance skeletal muscle transduction  
The data presented thus far suggests that changes in the structural conformation 
of VR1 alone are the driving force behind enhancements in transduction following 
mutation of position 265. Therefore, we sought to determine whether additional 
disruption to VR1 structure could produce a similar enhanced transduction phenotype. 
rAAV1 was thus mutated to generate S261del, S262del, A263del, S264del, G266del, 
A267del, S268del and N269del, as illustrated in Figure 2.6a. These constructs were 
injected into murine GC at 1e10vg, alongside rAAV1 and rAAV1/T265del. Transgene 
expression was quantified at 7 dpi (Figure 2.6b). Each mutant enhanced transduction 
efficiency to varying degrees relative to rAAV1. Transduction was enhanced by ≤3-fold 
in the S261, S262 and N269 deletion constructs. The G266 and S268 deletion 
constructs enhanced transduction by ~5-fold and the A263del and A267del by ~10-fold 
relative to rAAV1. The S264 and T265 deletion constructs enhanced transduction the 
most robustly over rAAV1, increasing transgene expression by 25- and 100-fold, 
respectively. These data indicate that any disruption made to the VR1 loop via deletion 
of an amino acid will enhance transduction in rAAV1, with such enhancement peaking 
via deletion of position 265 and tapering off as mutations are made further away from 
position 265 (Figure 2.6b).  
 
265 deletion mutants improve expression of a therapeutic transgene  
Finally, to compare the relative efficacy of the 265-deletion panel, six capsids 
were packaged with the hAAT expression cassette currently in clinical trial use[137]. 
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rAAV1, rAAV1/T265del, rAAV6, rAAV6/T265del, rAAV6.3 and rAAV6.3/T265del capsids 
were injected into murine GC at 1e10vg. Serum concentrations of hAAT were measured 
via ELISA 5 weeks post injection (Figure 2.7). In agreement with above, transgene 
expression was enhanced by deletion of position 265; however, the degree of 
enhancement did not reach the levels measured by luciferase assay (e.g., by ELISA 
there was a 9-fold increase in rAAV1/T265del expression over rAAV1, whereas the 
average measured by luciferase assay was >100-fold). Nonetheless, all 265 mutants 
outperformed parent serotypes, with rAAV6.3/T265del producing the greatest serum 
concentration of hAAT, producing approximately 12.5-fold more AAT per mL of serum 
than rAAV1.  
 
Discussion  
Success in the translation of rAAV gene therapy has been challenged by low 
transduction efficiency in vivo. This study employed structural analysis of the rAAV 
capsid to develop a rational engineering strategy that can clearly yield novel capsid 
variants with enhanced transduction phenotypes in skeletal muscle. The overall 
approach was made possible by earlier reports from our lab[133, 142], which uncovered 
VR1 as a key determinant of transduction efficiency in rAAV2. As we had previously 
discovered in rAAV2, enhancement of transduction was observed with substations of 
various amino acids at position 265 in rAAV1[142]. Remarkably, however, disruption of 
VR1 via the deletion of single amino acids in the more clinically relevant rAAV1 yielded 
novel vectors with transduction enhanced by orders of magnitude (Figure 2.1). This 
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observation alone has significant implications for patient dosing protocols currently 
utilizing rAAV1 and may lead to vector production easement moving forward. It was 
noted that in the rAAV6 capsid a similar outcome was obtained, but only after 
secondary mutations were created to disrupt the basic amino acid patch previously 
shown to confer heparan sulfate binding activity. Using a marker rescue approach made 
possible by analyzing capsid sequence homology, two distal regions of the capsid 
surface were defined that work in concert to modulate transduction efficiency and 
primary receptor recognition, shedding light on the complex role of capsid topology 
during the viral life-cycle.  
The antagonistic relationship between position 265 and primary receptor binding 
suggests that the 265 deletion phenotype results from a modification in protein:protein 
interactions between the capsid and a binding partner. Whether this occurs at initial 
attachment to the cell surface or during a post entry event remains to be determined. 
That the only measurable correlation to transgene expression was an increase in the 
number of vector genomes per cell, and not in expression kinetics or longevity, strongly 
suggests that the 265 phenotype is a result of alterations in cellular entry phenomena. 
VR1 has been implicated in receptor binding in rAAV2[154], as well as in a chimeric 
vector generated via directed evolution[155], though explicit structural details of the 
nature of these interactions have not yet been defined. The spatial relationship of 
position 265 relative to the protrusions that comprise the three-fold axis of symmetry – 
the primary region of the capsid responsible for receptor engagement – lends further 
evidence to this idea. Of note, no differences were seen between wild-type and mutant 
constructs in 1.) heat denaturation assays testing capsid stability, 2.) western blotting to 
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examine the ratio and size of capsid proteins, or 3.) electron microscopy to search for 
overt differences in capsid topology or population distribution of empty versus full 
capsids (data not shown). Furthermore, dose response data (not shown) suggest that 
the 265 enhanced transduction profile can be dialed in for respective clinical 
applications (e.g., AAT vs. lipoprotein lipase deficiency).  
It is well known that phosphorylation of threonine residues effects intracellular 
protein dynamics. Indeed, the phosphorylation of select serine, threonine and tyrosine 
residues on the rAAV capsid surface ultimately results in proteasomal clearance of 
capsids prior to transgene delivery and mutation of these residues to non-
phosphorylable species prevents capsid clearance, thereby enhancing transduction 
efficiency[132, 156]. That multiple different types of amino acid at position 265 (deletion 
of threonine, substitution with phosphomimetics or bulky hydrophobics) all enhanced 
transduction suggests that phosphorylation is not likely responsible for transduction 
enhancements mediated by 265 mutation. Furthermore, the structure of VR1 could be 
disrupted throughout the loop to obtain an improved transduction phenotype. It is 
possible that these disruptions relieve the capsid from interacting with an inhibitory 
protein, though this has yet to be determined. However, there is evidence of a similar 
effect in rAAV2, in which ablation of capsid heparin binding ability substantially improves 
transduction of muscle tissue[63, 85]. Indeed, such data was recapitulated in this work. 
It has been argued that the ability of rAAV2 to bind heparan sulfate proteoglycans has 
evolved through tissue culture adaptation of the virus and that binding to such receptors 
has been detrimental to the in vivo transduction efficiency of this serotype[157]. 
Likewise, in the case of adenovirus, robust hepatic transduction is maintained even 
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when the capsid is mutated to exclude binding to its primary tethering receptor, CAR, as 
alternate regions of the capsid are able to compensate by facilitating productive 
interactions with alternate receptors[158].  
It is interesting that transduction efficiency peaked following deletion of position 
265, specifically. In analyzing the hydrogen bonding network of VR1 in rAAV1 (Figure 
2.8A), it is noteworthy that a network of hydrogen bonds primarily orchestrated by 
position 265 stabilizes VR1. Indeed, the next best transducers resulted from deletion of 
positions 264 and 263, both of which also participate in the structural stabilization of 
VR1 via this network. Of course, the only way to truly examine the effects of these 
mutations on the stability of VR1 would be through crystallographic resolution of these 
constructs. It is significant, however, that rAAV6 is inherently less stabilized around 
position 265 (Figure 2.8B), and that in practice rAAV6 requires additional mutation to 
replicate the position 265 phenotype. Many studies have attempted to unravel the 
phenotypic disparity (e.g., differences in receptor preferences and tissue tropism) 
between the closely related rAAV1 and rAAV6. Virtually all previous studies have 
examined the six capsid amino acids that differ between these two viruses[84, 150, 159, 
160], with the understanding that pinpointing these locations allows dissection of capsid 
regions that directly influence the viral life-cycle. While this is true, we demonstrate here 
for the first time an additional, far subtler layer of capsid architecture that differs on a 
structural level between these two serotypes to regulate viral biology, along with a 
rational design approach to exploit these attributes.  
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Another compelling finding is the discrepancy of measured transduction 
enhancement between rAAV1 and rAAV1/T265del when examining transgene 
expression within injected tissue directly (i.e., ex vivo luciferase assay, which produced 
137-fold enhancement) versus measurement of transgene expression of a secreted 
protein (i.e., ELISA to determine the concentration of hAAT, which produced 9-fold 
enhancement). It is noteworthy that in previous experiments comparing the 
measurements of secreted hAAT from i.m.-injected rAAV2, rAAV2.5 and rAAV2/265D, 
no obvious differences were found by ELISA, despite order of magnitude increases in 
luciferase expression relative to rAAV2 when using the engineered capsids (Dr. 
Chengwen Li, unpublished). Likewise, while it has been found that the proteasome 
inhibitor Bortezomib can enhance rAAV2 transduction in liver tissue by approximately 
10-fold when measured by luciferase assay[161], that enhancement drops to less than 
2-fold when measuring serum for the expression of secreted Factor IX[121]. It is likely 
that measuring transgene expression directly from harvested tissue is a more sensitive 
technique than is the collection and subsequent measurement of secreted factors due 
to differences such as protein half-life within an intracellular environment versus serum, 
as well as overall efficiency of protein secretion relative to protein expression. Such 
findings highlight the exquisite increase in transduction that needs to be achieved for 
translatable applicability when designing rAAV vectors meant to deliver transgenes 
encoding secreted proteins.  
The goal of these efforts is the continued improvement of rAAV vector technology 
so that gene therapy becomes a more practical and effective clinical choice, such as 
through reducing vector dosing required to achieve therapeutically beneficial transgene 
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levels. Such efforts may allay clinical concerns around vector dose-dependent 
toxicity[162] and ease clinical-grade vector production efforts. Here we present a simple 
and effective strategy for improving the performance of rAAV serotypes currently being 
used in clinical trials targeting skeletal muscle by direct injection. As this strategy utilizes 
a region of the capsid unique to other major advancements in rAAV vector development 
(e.g., the Tyr-to-Phe capsid mutants[132]), it will be interesting to determine whether it 
can be integrated synergistically with such technological advancements to further 
optimize rAAV vectors for gene therapy. As we continue evaluating the potential of our 
265 mutant panel to target and enhance transgene expression in cardiac tissue, as well 
as whole body skeletal muscle following systemic administration, the work contained 
herein provides a starting foundation for the development of next generation 
translational rAAV vectors. Furthermore, we have produced a collection of rAAV capsid 
reagents available for further detailed (e.g. crystallographic) analysis that will eventually 
lead to a more comprehensive understanding of the unique and significant role that 
single amino acids play in rAAV vector biology. 
 
Materials and Methods  
Plasmids and viruses. All plasmids were obtained from the University of North 
Carolina Gene Therapy Center Vector Core facility. Virus was generated via triple 
transfection of HEK293 cells and purified by cesium chloride density ultracentrifugation. 
Viral titer was obtained using real time quantitative PCR (qPCR) analysis, using the 
following primer set designed to recognize the luciferase transgene: (forward) 5’-AAA 
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AGC ACT CTG ATT GAC AAA TAC-3’ and (reverse) 5’-CCT TCG CTT CAA AAA ATG 
GAA C-3’; or the following primer set designed to recognize human α1 anti-trypsin gene: 
(forward) 5’- GAA GTC AAG GAC ACC GAG GA-3’ and (reverse) 5’-CCC AGC TGG 
ACA GTC TCT TA-3’. For all experimental groups, relevant viral constructs were titered 
together on the same qPCR plate prior to being used. Site-directed mutagenesis 
(Stratagene QuikChange) was used for nucleotide deletion or substitution. Table 2.1 
lists the primer sequences used for all VR1 mutants examined in this study. rAAV1 -> 
rAAV6 point mutants (e.g., rAAV6.1, etc) were already part of general lab stocks. DNA 
sequencing was performed on each plasmid used in this work to verify sequence 
identity prior to making virus.  
Live-animal studies. All animals were maintained and treated in accordance with 
National Institutes of Health guidelines, under protocols approved by the IACUC at the 
University of North Carolina, Chapel Hill. rAAV variants packaging the either the CBA- 
luciferase or CBA-hAAT transgene were injected into the GC of 6-8 week old female 
BALB/c mice (Jackson Laboratories) at indicated quantities. All injections were 
performed in 50µL total volume per injection. Mice were anesthetized using isoflurane 
gas prior to injection. Luciferase transgene expression was monitored at indicated time 
points using a Xenogen IVIS Lumina imaging system (Perkin Elmer/Caliper Life 
Sciences) following intraperitoneal injection of D-luciferin substrate (Nanolight) at 
120mg/kg body weight. Bioluminescent image analysis was performed using Living 
Image soft- ware (Perkin Elmer/Caliper Life Sciences), and luciferase expression is 
reported in CPM/ROI (counts per minute over a selected region of interest).  
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Ex vivo quantitation of transgene expression and copy number. For ex vivo 
luciferase assay, mice were sacrificed at 7dpi of 1e10vg and injected muscle tissue 
harvested. Approximately 50mg of each tissue was minced on ice. Each tissue aliquot 
was then homogenized in 150µL of 2X Passive Lysis Buffer (Promega) using a Tissue 
Tearor (Cole-Parmer). 35µL of lysates and 100µL of D-luciferin substrate (Promega) 
were transferred to 96-well plates for luminometric analysis using a Victor2 luminometer 
(Perkin Elmer). Total protein concentration in tissue lysates was determined via 
Bradford assay (Bio-Rad). At 3dpi of 1e10vg, injected GC was harvested/homogenized 
and lysed as above, and a ~25mg tissue aliquot was processed using a DNeasy kit 
(Qiagen) to extract host and vector genomic DNA. The number of cells was determined 
via qPCR with the following primers designed specific to the mouse Lamin (a 
housekeeping gene): (forward) 5’-GGA CCC AAG GAC TAC CTC AAG GG-3’ and 
(reverse) 5’-AGG GCA CCT CCA TCT CGG AAA C-3’. The number of viral genomes 
per cell was determined via qPCR with primers designed specific to the luciferase 
transgene, as described above.  
Heparin competition. Indicated constructs were incubated in either a 250µg/mL 
solution of porcine heparan sulfate sodium salt (Sigma-Aldrich) dissolved in Ringer’s 
saline solution (RSS), or Ringer’s saline solution alone, overnight at 4°C with rotation. 
1e10vg of each group was injected per GC in a total volume of 50µL per injection. At 
7dpi, live animal bioluminescent imaging was performed.  
Molecular modeling. The three-dimensional structures of rAAV1, rAAV2 or rAAV6 
were displayed as whole capsids (a kind gift from Dr. Mavis Agbandje-McKenna) using 
previously published coordinates in PyMol (www.pymol.org). The PyMol align command 
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was used to align various structures. Atom pairs involved in hydrogen bonding were 
calculated on crystal structure coordinates using MolProbity 
(http://molprobity.biochem.duke.edu) and visualized using KiNG graphics software 
(kinemage.biochem.duke.edu).  
Heparin affinity chromatography. Indicated constructs were incubated with 
heparan sulfate conjugated agarose beads (Sigma-Aldrich) overnight at 4°C with 
rotation. Slurry was transferred to a micro chromatography column (Bio-Rad) and 
washed 3 times with RSS, followed by increasingly stringent NaCl washes. Solutions 
were made by dissolving appropriate quantity of NaCl into RSS, after adjusting for 
amount of NaCl already present in the solution. All wash fractions were collected. 
Percent virus contained in each fraction was determined by qPCR quantification of viral 
particles contained within each wash, using primers designed against the luciferase 
transgene, described above.   
ELISA detection of human AAT. Mouse blood was collected via retro-orbital 
bleed using heparinized capillary tubes (Sigma-Aldrich). Immediately following 
collection, samples were pelleted and serum collected and stored at -80°C for future 
use. Mice were anesthetized with isoflurane gas prior to bleeding. A 96-well plate was 
coated with rabbit anti-human AAT antibody (Sigma-Aldrich) at 10mg/mL overnight at 
4°C. Plate was then washed and blocked with serum dilution solution (1XPBS with 2.5% 
bovine albumin and 0.05% Tween) for 1 hour at room temperature. Indicated serum 
dilutions (100µL total per each sample) were added to plate and incubated for 2 hours 
at room temperature. After washing 4 times with 1XPBS, 100µL of HRP-conjugated 
goat anti-human AAT antibody (10ug/mL; Abcam) was added to plate for 1 hour at room 
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temperature. After further washing, color was developed by addition of the TMB 
substrate (Pierce) and arrested by 10% H2SO4. Optical density was read using an 
iMark microplate reader (Bio-Rad). Murine AAT was not detectable with this assay.  
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Figure 2.1. In vivo characterization of rAAV1 position 265 mutants following 
i.m. injection. (a) Mice were administered 1e10vg into the GC. Luciferase transgene 
expression was visualized and quantified using live animal bioluminescent imaging at 
7dpi. Units displayed are counts per minute over region of interest (CPM/ROI). For 
visualization purposes, rAAV1 is shown on a different scale than the 265 mutants. This 
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does not effect image quantitation. For ex vivo quantification of transduction phenotype 
(b), injected muscle was harvested and lysed, and luciferase assay performed on tissue 
lysate. Measurements depicted as relative light units normalized to mg total protein 
(RLU/mg protein). (c) Viral transgene copy numbers per cell (vg/cg) were measured 
using qPCR. (d) A time course of expression kinetics was performed on rAAV1 and 
rAAV1/ T265del following injection of 1e10vg. All data represents n=4 per group; in 
panel (a) one representative image is displayed per group.  
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Figure 2.2. Phenotype of 265 deletion mutant in rAAV6. (a) Luciferase transgene 
expression 7dpi of 1e10 vg of either rAAV6 or rAAV6/T265del. (b) Alignment of the VR1 
capsid region of rAAV1 (light grey) and rAAV6 (dark grey). Residue 265 is highlighted in 
dark blue on rAAV1 and in yellow on rAAV6. Image generated in PyMol using available 
crystallographic coordinates for these capsids. (c) Transgene expression following 
injection of rAAV1->rAAV6 point mutants into mouse GC. Data represented as fold 
difference relative to measured expression of rAAV6. All data represents n=4 per group.  
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Figure 2.3. Visualization of amino acid positions 265 and 531 on the rAAV6 
capsid. PyMol depiction of the crystallographic coordinates of the rAAV6 capsid (a), 
with each icosahedral axis of symmetry labeled. (b) Close up of the 3-fold axis of 
symmetry, with residues 265 and 531 colored purple and orange, and denoted by 
arrows. (c) Close up of the 5-fold axis of symmetry, with residues 265 and 531 colored 
purple and orange, and denoted by arrows. (d) Close up of the 2-fold axis of symmetry, 
with residues 265 and 531 colored purple and orange, and denoted by arrows.  
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Figure 2.4. Effect of capsid:heparin interactions on the transduction 
phenotype of 265 mutation. (a) Transgene expression 7dpi of rAAV2 capsid mutants 
into the GC. (b) PyMol depiction of the rAAV6 capsid with residues T265 (purple), K531 
(orange) and R585 (blue) denoted, in the context of the 3-fold axis of symmetry. Dashed 
circle represents general outline of heparin binding footprint. (c) Transgene expression 
of rAAV2 and rAAV1 constructs injected into GC following preincubation in either a 
saline or heparan sulfate solution. All data represents n=4 per group.  
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Figure 2.5. Heparin affinity chromatography elution profiles of rAAV2 and 
rAAV6 constructs used in this study.  rAAV2 (a, b) and rAAV6 (c, d) constructs used 
in this study were incubated with heparin-conjugated agarose beads and then eluted 
from beads using increasingly stringent NaCl washes. Elution profiles were collected by 
quantifying the number of viral genomes present in each eluted fraction using RT-
qPCR. Experiments were repeated in triplicate; one representative chromatogram is 
shown per group.  
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Figure 2.6. Transgene expression of VR1 deletion scanning mutants in the 
rAAV1 capsid. Single deletion mutations were created in the VR1 loop of the rAAV1 
capsid, and constructs were injected into mouse GC at a dose of 1e10vg. Transgene 
expression is depicted as fold difference relative to that measured following injection of 
rAAV1. Cartoon above graph depicts residues that were mutated for this study in grey, 
with position 265 depicted in black. The location of N- and C-terminal beta sheets 
surrounding VR1 is also shown. Data is representative of n=4 per group.  
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Figure 2.7. Serum concentration of hAAT following i.m. injection of rAAV1 
and rAAV6 constructs. rAAV1 and rAAV6 capsid packaging an hAAT transgene were 
injected into GC muscle at a dose of 1e10vg. 5 weeks post injection, serum was 
collected and ELISA used to determine quantities of hAAT protein within the blood. Data 
represents n=4 per group.  
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Figure 2.8. Hydrogen bonds in VR1 region of rAAV1 and rAAV6 capsids. 
Atom pairs involved in hydrogen bond formation were calculated for (a) rAAV1 and (b) 
rAAV6 crystallographic coordinates using MolProbity all atom contact analysis and 
visualized using KiNG graphics program. Residues comprising the VR1 loop are 
labeled. Hydrogen bonds generated from residue 265 are visualized using green dots 
and are indicated by arrows. VR1 side chains are colored orange and the protein 
backbone is colored yellow.  
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Table 2.1. Primers used to create constructs that were investigated in Chapter 2. 
 
 	  
 
Construct 
 
 
Primer Sequence (5’ -> 3’) 
rAAV1/T265D gca atc tcc agt gct tca gac ggg gcc agc aac g 
rAAV1/T265E gca atc tcc agt gct tca gag ggg gcc agc aac g 
rAAV1/T265F gca atc tcc agt gct tca ttc ggg gcc agc aac gac 
rAAV1/S261del caa gca aat cag tgc ttc aac ggg gg 
rAAV1/S262del gca aat ctc cgc ttc aac ggg gg 
rAAV1/A263del gca aat ctc cag ttc aac ggg ggc 
rAAV1/S264del caa atc tcc agt gct acg ggg gcc aga aac 
rAAV1/T265del* ctc cag tgc ttc agg ggc cag caa cg 
rAAV1/G266del cca gtg ctt caa cgg cc gca agc 
rAAV1/A267del gct tca acg ggg agc aac gac aac c 
rAAV1/S268del cgg ggg cca acg aca acc ac 
rAAV1/N269del cgg ggg cca gcg aca acc act tc 
 
*exact rAAV1/T265del primer was used to create rAAV6/T265del mutants. 
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     CHAPTER III: 
DEFINING CONSERVED STRUCTURAL COMPONENTS OF THE AAV 
CAPSID THAT ENABLE TISSUE-SPECIFIC TRANSDUCTION FOLLOWING 
SYSTEMIC ADMINISTRATION 
 
Summary 
 
We have previously correlated the destabilization of hydrogen bond networks 
within recombinant adeno-associated viral (rAAV) capsid surface loop variable region 1 
(VR1) to transduction efficiency following intramuscular injection. To investigate the 
utility of this finding for systemic applications, the capsid structures of rAAV serotypes 1 
through 9 were computationally analyzed and VR1 residues participating in hydrogen 
bonding were individually deleted. Mutant capsids were assessed for tissue tropism and 
transduction efficiency following intravenous administration into mice. Ex vivo luciferase 
assays revealed increased muscle transduction and targeting in five of the nine 
serotypes (rAAV1, rAAV6, rAAV7, rAAV8, rAAV9); cardiac and skeletal muscle 
transduction were enhanced by up to 170-fold and 9027-fold over parental serotypes, 
while hepatic transduction was decreased up to 427-fold. VR1 stability also appeared 
critical to the remaining serotypes, as VR1 deletion mutations rendered rAAV2 and 
rAAV3b defective in transduction, and rAAV4 and rAAV5 defective in virion production. 
Intriguingly, amino acid insertions into VR1 produced an opposing phenotype: rAAV1, 
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rAAV2, rAAV3b, and rAAV6 capsids could instead be targeted to transduce the liver 
with high efficiency, increasing hepatic transduction up to 132-fold. Finally, VR1 
mutation synergized with established tyrosine-to-phenylalanine mutations to further 
increase transduction efficiency while maintaining preferential cardiac/skeletal muscle 
targeting. 
 
 
INTRODUCTION 
 
Recombinant adeno-associated virus (rAAV) has become a successful human 
gene therapy vector in a variety of clinical settings [163]. Efforts to administer rAAV in 
the clinical setting have primarily employed vector administration directly into the tissues 
in need of gene correction [163]. While this may be the ideal route of administration for 
small and easily accessible sites like the eye [164], attempting to treat a larger area 
such as skeletal muscle is a far more ambitious endeavor [3]. For example, the recently 
approved gene therapy treatment Glybera requires up to 60 intramuscular injections in 
order to elicit a therapeutic effect [165], and the resultant tissue inflammation requires 
patient sedation and immune suppression prior to treatment. From a delivery 
perspective, the ability to target select tissues following intravenous infusion of vector 
could relieve such burdens and expand the capacity of rAAV as a gene therapy vector. 
As all naturally occurring AAV variants isolated to date preferentially transduce the liver 
when injected intravenously [4], the delivery of therapeutic genes to alternative tissues 
requires laboratory-derived virions engineered with novel transduction properties [166]. 
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There are two general approaches towards creating such vectors: 1.) transcriptional 
targeting using regulatory elements such as tissue-specific promoters [122, 167] or 
micro RNAs [17]; 2.) viral capsid modification via methods such as directed evolution 
[166] or manipulation of receptor binding footprints [17]. Though transcriptional 
regulation can effectively restrain transgene expression to selected tissues, they do not 
preclude the sequestration of capsids in the liver [122, 168]. This creates inefficiencies 
that can only be remedied by the administration of high vector doses and leads to 
potential safety concerns regarding vector immunogenicity [100, 111, 169-171] and 
genotoxicity [172]. Likewise, though directed evolution approaches can successfully 
produce vectors that robustly target a given tissue, it is difficult to concurrently to 
prevent transduction in unintended tissues. Furthermore, capsids derived from this 
approach frequently exhibit such diversity in capsid protein sequence that it becomes 
challenging to biologically interpret resultant phenotypes [173]. Manipulating receptor 
binding footprints on the capsid surface overcomes many of these issues [63, 85, 87], 
but is only useful for a handful of serotypes in which receptor binding regions are 
known. 
To sustainably develop new logical methods of rAAV vector optimization, it is 
necessary to continue delineating a functional understanding of rAAV capsid biology. 
rAAV is particularly amenable to such efforts as the core β-barrel structure of the capsid 
monomer is highly conserved amongst serotypes, with significant structural variability 
found primarily in the surface loops punctuating the capsid surface [60]. These regions 
of diversity, termed variable regions (VRs), impart the features that are unique to each 
serotype (e.g., transduction efficiency, receptor binding preferences, etc) and provide 
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clues for determining the role of the various topological features comprising the capsid 
surface [60]. For example, serotype-comparative protein sequence analysis facilitated 
the discovery that the transduction efficiency of rAAV2 in skeletal muscle following 
intramuscular injection is highly influenced by the amino acid composition of variable 
region 1 (VR1) [133, 142]. Furthermore, when examining this finding in the context of 
the rAAV1 capsid, it was discovered that VR1 structural stability correlated with the 
capacity of this serotype to transduce muscle [174]. Specifically, when select amino acid 
deletion mutations were made in VR1 of rAAV1, transduction was enhanced by several 
log orders. Computational analysis revealed that these mutations ablated intra-loop VR1 
hydrogen bond networks, leading to a regional destabilization of the capsid [174].  
Here, we extended the above findings to create a panel of rAAV vectors 
selectively targeted to transduce skeletal and/or cardiac muscle tissues following 
intravenous injection. To accomplish this, we computationally analyzed serotypes 
rAAV1-rAAV9 to identify the corresponding VR1 hydrogen bond networks and made 
targeted amino acid deletion mutations to destabilize these networks. Mutant capsids 
were then systemically administered to mice and biodistribution phenotypes were 
quantified ex vivo. Six vectors in our collection produced a more targeted cardiac 
biodistribution profile than rAAV9, the serotype considered to have the greatest cardiac 
tissue targeting and transduction capabilities [175-177].  Relative to their wild-type 
counterparts, all VR1 mutant capsids were additionally detargeted from transducing 
hepatic tissues by orders of magnitude. Intriguingly, in contrast to the VR1 deletion 
mutants, capsids bearing VR1 amino acid insertions targeted and transduced hepatic 
tissue with greater efficiency than their parental counterparts. Therefore, it appears that 
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in certain cases VR1 can be manipulated to act like a biological switch in controlling 
tissue tropism based on the selected amino acid mutation. Finally, we demonstrated 
that VR1 mutations can be synergistically integrated with established tyrosine-to-
phenylalanine mutations [178] to further enhance transduction efficiency while 
maintaining favorable biodistribution phenotypes. Thus, our strategy can be combined 
with existing advancements in rAAV capsid technology to create true next generation 
translational vectors. 
The ability to optimize numerous serotypes as candidate reagents for muscle- or 
liver-oriented therapeutic applications may help facilitate a patient-personalized 
approach to gene therapy, as it widens the range of available serotypes that can be 
used to treat a given disorder and alleviates having to rely on a single serotype’s innate 
transduction properties. For example, this may facilitate the pairing of serotype to 
patient based on the patient’s preexisting neutralizing antibody profile [5]). Furthermore, 
being able to choose amongst a collection of capsids for a given application improves 
the ability to re-administer vector on multiple occasions if necessary. In summary, 
rationally engineering VR1 is a promising approach towards expanding rAAV’s 
therapeutic repertoire and provides novel insights into structural components of the 
capsid that can modulate tissue targeting and transduction efficiency.   
 
 
 
 
 
	   59	  
 
RESULTS 
 
Structural analysis of the rAAV capsid to identify hydrogen bond networks in VR1       
           We have previously demonstrated that the deletion of select amino acids within 
VR1 of the rAAV1 capsid leads to log order increases in transduction efficiency 
following intramuscular injection into mice [174]. Analysis of the rAAV1 crystal structure 
revealed that the most efficient VR1 deletion mutations corresponded to amino acids 
participating in intra-loop hydrogen bond networks, suggesting that the destabilization of 
VR1 structural elements leads to enhanced transduction phenotypes. The goal of the 
present study was to determine: 1.) whether rAAV1 VR1 mutant capsids can efficiently 
target muscle tissue following intravenous injection (versus simply having a phenotype 
of enhanced transduction), and 2.) whether the targeted destabilization of VR1 
structural elements is a conserved method of improving transduction in additional rAAV 
serotypes. To address these questions, a collection of rAAV capsids including rAAV1, 
rAAV2, rAAV3, rAAV4, rAAV5, rAAV6, rAAV7, rAAV8, and rAAV9 were analyzed with 
the open source structural validation software MolProbity [179] and VR1 hydrogen bond 
patterns visualized in KiNG [180] (Figure 3.8, A-H). These serotypes were chosen for 
analysis based on the availability of both capsid crystal structure data [51, 53, 57, 60, 
141, 181-183] and pre-existing knowledge of their in vivo transduction phenotypes [4]. 
There is no publicly available structural information for rAAV7; however, this serotype 
was included for the sake of completeness. For ease of visualization, identified 
hydrogen bond patterns were then translated into PyMol images (Figure 3.1, A-H). 
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Based on these analyses, amino acids from each serotype that were found to 
participate in intra-loop VR1 hydrogen bond networks were selected for deletion. Table 
3.1 lists the VR1 amino acid sequence for serotypes rAAV1-rAAV9 and the amino acids 
chosen for mutation in this study, as well as how many hydrogen bonds are 
hypothesized to be broken with each mutation. In the case of rAAV7, mutation of the 
threonine at position 265 was chosen based on previous results obtained for rAAV1 
[174]. In the case of rAAV9, the structure of VR1 appears to be stabilized by hydrogen 
bonds in two locations, the first primarily orchestrated by bonds originating around 
residue S263, and the second by bonds originating around residue S265. Therefore, 
mutant capsids comprising rAAV9/S263del and rAAV9/S265del were created, in 
addition to the double mutant rAAV9/S263del_S265del.  However, the double deletion 
mutant was unable to produce intact viral particles, which lead to the alternate strategy 
of mutating position S263 to an alanine in conjunction with deletion of position S265, to 
create rAAV9/S263A_S265del. For detailed atomic descriptions of the hydrogen bond 
relationships observed for all of the serotypes included within this study, refer to the 
legend for Figure 3.8.  
 
Biodistribution of rAAV capsids mutated to destabilize hydrogen bond networks in VR1 
To visualize tissue distribution and transduction efficiency of the above detailed 
wild-type and VR1 mutant capsids, each member of the collection was packaged with 
the chicken β-actin promoter driven firefly luciferase (CBA-luc) reporter transgene and 
injected into mice via the tail vein at a dose of 1e11 viral genomes (vg) per injection. 
Live-animal bioluminescent imaging was performed at 9 days post injection (dpi). At 10 
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dpi, mice were sacrificed and select organs removed, homogenized and lysed. Vector 
biodistribution was then quantified by subjecting tissue lysates to ex vivo luciferase 
assays in order to measure transgene expression, and qPCR analysis to quantify viral 
genome copy numbers per cell. The deletion of VR1 amino acids resulted in four 
phenotypes: 1.) selective and robust targeting of cardiac and/or skeletal muscle, as 
observed for rAAV1 and rAAV6 (Figure 3.2); 2.) maintenance of innate cardiac and/or 
skeletal muscle transduction efficiency, coupled with a substantial reduction in 
transduction of the liver, as seen in rAAV7, rAAV8, and rAAV9 (Figure 3.3); 3.) a 
widespread absence of transduction, as in rAAV2 and rAAV3 (Figure 3.9a, b); and, 4.) 
the inability to produce intact viral particles, as in the case of rAAV4 and rAAV5. 
VR1 mutations in rAAV1 and rAAV6 capsids led to substantial gains in 
transduction efficiency in cardiac and skeletal muscle tissues (Figure 3.2). Transgene 
expression measured 21-fold higher in cardiac and 26-fold higher in gastrocnemius 
(GC) tissue samples taken from mice treated with rAAV1/T265del versus rAAV1. 
rAAV1/T265del transduction efficiency was also enhanced in several other tissue types, 
including the diaphragm (26-fold), the spleen (3.5 fold), the kidney (5-fold), the pancreas 
(6-fold), and the lung (8-fold), (Figure 3.10a).  Surprisingly, there was a 3.5-fold 
decrease in hepatic transduction relative to rAAV1 (Figure 3.2b). Similarly, 
rAAV6/T265del capsids transduced cardiac and GC muscle at levels 14-fold and 3-fold 
higher then wild-type rAAV6, concomitant with a 28-fold decrease in transduction of the 
liver (Figure 3.2e). There were no remarkable differences in measured transgene 
expression between rAAV6 and rAAV6/T265del capsids in any other tissue tested 
(Figure 3.10b). rAAV6/S262del produced a similar phenotype to rAAV6/T265del, 
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transducing at levels 3.5-fold lower and 6-fold higher then rAAV6/T265del in cardiac and 
GC muscle, respectively, and within 1-fold of rAAV6/T265del in the liver (Figure 3.10c). 
These results suggest that rAAV1 and rAAV6 VR1 mutant constructs preferentially 
transduce muscle tissue when systemically administered to mice.   
The numbers of vector genomes present per host cell were quantified via qPCR 
on a subset of organs including the heart, GC, and liver (Figures 3.2c, f). In tissue 
samples obtained from mice treated with rAAV1/T265del and rAAV6/T265del capsids, 
changes in host cell transgene populations measured by qPCR trended similarly to 
those observed for transgene expression measured by luciferase assay (i.e., more 
vector genomes correlated with increased transgene expression, and vice-versa). 
However, differences amongst transgene population measurements were more subtle 
than those obtained for transduction efficiency.  For example, in mice treated with 
rAAV6/T265del there were 4-fold more vector genomes per heart cell than in mice 
treated with rAAV6, whereas there was a 14-fold increase in cardiac transduction with 
the mutant capsid (Figure 3.2f). Likewise, there were 4-fold fewer rAAV6/T265del 
genomes per liver cell, versus a 28-fold decrease in transduction. Intriguingly, vector 
genomes per cardiac cell were substantially lower than those measured per liver cell in 
the case of both rAAV1 and rAAV1/T265del, despite that transduction of the heart was 
far greater than that of the liver in both constructs. Collectively, these data indicate that 
the reduced ability of rAAV1 and rAAV6 VR1 mutant capsids to transduce the liver 
corresponds with an inability of these capsids to deliver a persistent transgene to 
hepatic cells. Additionally, transgenes delivered by VR1 mutant capsids to muscle 
tissues appear to be more effectively expressed than those delivered by their wild-type 
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counterparts. Finally, it would appear that some facet of the liver’s microenvironment 
imposes a hurdle towards the rAAV1 capsid’s ability to either enter the nucleus or 
uncoat once there.  
Deleting VR1 amino acids from rAAV7, rAAV8 and rAAV9 capsids created 
biodistribution profiles with strikingly similar phenotypes (Figure 3.3a, b, g). The primary 
feature observed for each was a sharp reduction in hepatic transduction (427-fold in 
rAAV7, 23-fold in rAAV8 and 107-fold in rAAV9 relative to wild-type capsids), while 
native cardiac and skeletal muscle transduction levels were maintained. Transduction 
efficiency in muscle tissue did not markedly change between rAAV7 and 
rAAV7/T265del; however, rAAV8/T265del enhanced transduction efficiency in GC 
tissue by approximately 8-fold relative to rAAV8 (Figure 3.3e). rAAV9/S263del_S265del 
produced variable effects in muscle tissue, transducing cardiac tissue 3-fold lower and 
GC tissue 2-fold higher than rAAV9 (Figure 3.3h). There were no prominent 
transduction differences between VR1 mutant and wild-type capsids of this subset in 
any other tissue type sampled (Figure 3.11a-c). It is notable that simultaneous 
mutations at positions S263 and S265 were required to produce a muscle-targeted 
biodistribution profile in rAAV9, and that single deletions at either of these positions 
substantially reduced overall transduction efficiency (Figure 3.11d).  
The numbers of vector genome copies present per host cells were quantified in 
cardiac, GC and hepatic tissue samples. In all VR1 mutant capsids of this subset, 
reduced hepatic transgene expression corresponded to reduced transgene populations 
within liver cells (85-fold fewer vector genomes per liver cell for rAAV7/T265del, 27-fold 
fewer for rAAV8/T265del and 7-fold fewer for rAAV9/S263del_S265del; Figures 3.3c, f, 
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i). The relationship between transgene population and transduction efficiency was less 
clear in muscle tissue samples. For example, there was a 22-fold reduction in transgene 
copies per cardiac cell when comparing rAAV7/T265del to rAAV7, yet transduction 
efficiency between the capsids was virtually the same. These data suggest that VR1 
mutant capsids of this subset are deficient in the ability to deliver a stable transgene 
population to hepatic cells, while transgenes delivered by these capsids to muscle 
tissues are more effectively expressed than those delivered by their wild-type 
counterparts. 
The deletion of VR1 amino acids produced deleterious effects in rAAV2, rAAV3b, 
rAAV4 and rAAV5 capsids. In rAAV4 and rAAV5, VR1 amino acid deletions led to an 
inability to produce intact virions. Vector production was attempted several times with 
both constructs to verify the repeatability of this result. In rAAV2 and rAAV3b, VR1 
amino acid deletions had no measurable impact on vector production; however, in both 
of these serotypes VR1 deletion mutations resulted in the elimination of measurable 
transduction in mice following intravenous injection (Figure 3.9a, b). Again, to verify the 
repeatability of these results, these experiments were duplicated with fresh stocks of 
vector in a second cohort of mice at a 5-fold higher dose (5e11vg/injection) of rAAV2 
and rAAV2/S264del (Figure 3.9c). Overall, the dramatic effects observed in these 
serotypes in response to VR1 deletion mutations suggests that maintaining a defined 
VR1 structure is critical towards these capsids’ abilities to complete a productive viral 
life-cycle.  
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Identification of a capsid motif that enables highly efficient hepatic transduction 
Previous studies have demonstrated that rAAV2 capsids harboring amino acid 
insertion mutations following position 264 in the capsid protein (creating a de novo 
position 265) exhibit markedly enhanced transduction efficiency in skeletal muscle 
following intramuscular injection [133, 142]. The insertion of aspartic acid in particular 
(rAAV2/265D) has been found to enhance transduction by orders of magnitude [142]. 
As the deletion of VR1 amino acids rendered rAAV2 capsids incapable of transduction, 
we next examined whether the alternative – the insertion of amino acids into VR1 – 
could enhance the biodistribution phenotype of rAAV2. rAAV2 and rAAV2/265D capsids 
packaging CBA-luc were injected into the tail vein of mice and live animal 
bioluminescent imaging was performed at 9dpi (Figure 3.4a). At 10dpi organs were 
harvested and quantified for transgene expression, as described above. Intriguingly, 
while VR1 amino acid deletions in other serotypes led to sharp reductions in hepatic 
transduction, the insertion of additional amino acids into VR1 led to an opposite 
phenotype. Hepatic transduction was increased by 10-fold in rAAV2/265D relative to 
rAAV2 (Figure 3.4b), while transduction differences between the two capsids differed 
by ≤2-fold in all other tissues studied (Figure 3.4b and Figure 3.12a). Vector genome 
copies per host cell differed by less than 1-fold between the two capsids in heart and 
GC tissues; however, there was a 10-fold increase in vector genome copies per liver 
cell in mice administered rAAV2/265D versus rAAV2 (Figure 3.4c). Thus, rAAV2/265D 
capsids are either more capable of targeting to and entering liver cells than are rAAV2 
capsids, or the genomes delivered by these mutant capsids are better able to persist 
within these cells (or both). 
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To determine whether the presence of an aspartic acid in VR1 could enhance 
hepatic transduction in additional serotypes, substitution mutations (Table 3.2) were 
made in rAAV1 (rAAV1/T265D) and rAAV6 (rAAV6/T265D), and an insertion mutation 
was made in rAAV3b (rAAV3b/265D). In all cases, a strong transduction preference for 
the liver was observed: rAAV1/T265D transduced the liver by approximately 212.5-fold 
higher than rAAV1 (Figure 3.4h), rAAV6/T265D by 28-fold relative to rAAV6 (Figure 
3.4k), and rAAV3b/265D by 9-fold relative to rAAV3b (Figure 3.4e). In the case of 
rAAV1 and rAAV1/T265D, transduction differences between the two constructs differed 
by 2.5-fold or less in all other tissues examined (Figure 3.4h and Figure 3.12c). 
rAAV6/T265D enhanced transduction of cardiac and GC muscle relative to rAAV6 by 
32- and 4.5-fold, respectively (Figure 3.4k).  In all remaining tissues, transduction 
efficiencies of the two constructs were virtually identical (Figure 3.12d). Finally, when 
comparing the biodistribution of rAAV3b and rAAV3b/265D, the mutant construct 
enhanced transduction by approximately 3-fold in cardiac and diaphragm tissues, while 
no remarkable transduction differences between the two constructs were observed in 
any remaining tissues (Figure 3.4e and Figure 3.12b). Taken together, the data show 
that the insertion or substitution of aspartic acid into VR1 preferentially enhances 
hepatic transduction following intravenous administration of rAAV. 
To determine if transduction efficiency correlated with genome copy number 
within each tissue, vector genome copies per host cell were quantified for heart, liver, 
and GC tissue samples. There were increased numbers of vector genomes present in 
the livers of mice treated with rAAV1/T265D and rAAV3b/265D relative to wild-type 
counterparts (4.5-fold and 182-fold, respectively; Figure 3.4f, i). In the case of rAAV6, 
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vector genome copies per liver cell were virtually identical between wild-type and 
mutant capsids (Figure 3.4l). VR1 aspartic acid mutations also substantially enhanced 
the number of vector genome copies per GC cell in mice treated with rAAV1/T265D or 
rAAV3b/T265D (60-fold and 51-fold more genomes than wild-type, respectively; Figure 
3.4f, i, l), though transduction efficiencies between mutant and wild-type constructs in 
this tissue type were identical (in either case, values measured within 2-fold of those 
obtained for wild-type capsids). The lack of consistent correlation between vector 
genome copy numbers and transduction efficiencies strongly suggests that post entry 
processing of viral capsids is at least partially responsible for driving the enhanced liver 
transduction efficiencies of these mutant capsids.  
While rAAV1, rAAV2, rAAV3b and rAAV6 capsids were made to contain the 
same SSXSDGAS VR1 amino acid sequence following 265D mutation, rAAV8 and 
rAAV9 have substantially different amino acid sequences in this region of the capsid 
(Table 3.2). Therefore, to clarify whether the enhanced preferential liver transduction 
produced by capsids bearing a 265D mutation was due to primary amino acid sequence 
versus some electrostatic or structural effect imparted by aspartic acid itself, 265D 
mutations were made in rAAV8 and rAAV9 capsids. rAAV8/T265D and rAAV9/T265D 
capsids packaging CBA-luc were produced in tandem with rAAV8 and rAAV9, and all 
were intravenously injected into mice. Bioluminescent imaging was performed at 10dpi. 
In rAAV8 and rAAV9 capsids, the T265D mutation substantially reduced overall 
transduction efficiency relative to wild-type capsids (Figure 3.13). These results suggest 
that the SSXSDGAS VR1 amino acid sequence is the driving force behind enhanced 
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hepatic transduction efficiency in the relevant rAAV capsids, and not a structural feature 
imparted by aspartic acid itself. 
 
Impact of capsid heparin binding ability on transduction efficiency of VR1 mutant 
capsids 
We have previously demonstrated that the ability of a given capsid to bind to 
heparan sulfate impedes the enhanced transduction phenotype produced by VR1 
mutation in capsids administered via intramuscular injection [174]. It has been 
previously shown that heparin binding can be disrupted in rAAV2, rAAV3b, and rAAV6 
through single point mutations in each capsid [62, 63, 150, 152]. Therefore, to 
determine whether VR1 mutant capsid transduction efficiency could be further 
enhanced, these mutations were incorporated into rAAV2, rAAV3b, and rAAV6 to create 
rAAV2/R585E, rAAV3b/R594A, and rAAV6/K531E. The inability of these mutant capsids 
to interact with heparin was verified using heparin affinity chromatography (data not 
shown). The above capsids were packaged with CBA-luc and intravenously 
administered to mice in tandem with rAAV2/265D_R585E, rAAV3b/265D_594A, and 
rAAV6/T265D_K531E and their single mutant and wild-type counterparts. At 10dpi, 
mice were sacrificed and livers removed for quantitation of transgene expression. As 
has been previously shown [63, 85], impairing heparin binding from the rAAV2 capsid 
decreased hepatic transduction in mice by about 6.5-fold (Figure 3.5a). However, when 
combining this heparin-null rAAV2 capsid with the VR1 mutation 265D, the resultant 
rAAV2/265D_R585E outperformed both rAAV2 and rAAV2/265D in the liver by 132- and 
11-fold, respectively (Figure 3.5a). Impairing capsid heparin binding ability in rAAV3b 
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and rAAV6 in combination with the VR1 265D mutation also enhanced transduction 
compared to the respective parent capsids. rAAV3b/265D_R594A transduced the liver 
by 53-fold over rAAV3b and 2.5-fold over rAAV3b.265D, while rAAV6/T265D_K531E 
was respectively 46-fold and 4-fold more efficient than rAAV6 and rAAV6/T265D 
(Figure 3.5b, c). Finally, because VR1 deletion mutations applied to rAAV6 capsids 
enhanced transduction efficiency in muscle tissue (unlike similar mutations in rAAV2 
and rAAV3b which became transduction deficient following VR1 amino acid deletions), 
we also sought to determine whether nullification of rAAV6 heparin binding would serve 
to further increase transduction within this context. Individual mice were administered 
1e11vg of rAAV6, rAAV6/T265del, rAAV6/K531E or rAAV6/T265del_K531E. At 10dpi, 
mice were sacrificed and heart and GC samples removed to determine ex vivo 
luciferase expression. As with rAAV6/T265D, above, abrogation of rAAV6 capsid 
heparin binding ability further enhanced the transduction efficiency of rAAV6/T265del. 
rAAV6/T265del_K531E was 170-fold and 13-fold more efficient at transducing cardiac 
tissue than rAAV6 and rAAV6/T265del, respectively, 9027-fold and 2795-fold more 
efficient than each in GC tissue (Figure 3.5d). Taken together, these studies indicate 
that in order to optimize the transduction efficiency of VR1 mutant capsids, it is 
necessary to ensure that capsid heparin binding capabilities are removed from the 
applicable serotypes. 
 
Transduction of VR1 mutant capsids relative to most efficient wild-type serotypes 
When delivered intravenously into mice, rAAV8 and rAAV9 are generally 
considered to be the most efficient serotypes at transducing hepatic and cardiac tissue, 
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respectively [176, 184]. Therefore, to adequately assess the in vivo performance of our 
collection of VR1 mutant capsids within the context of existing reagents, capsids 
bearing VR1 deletion mutations and those bearing VR1 insertion mutations were 
evaluated in tandem with rAAV9 and rAAV8, respectively. rAAV1/T265del, 
rAAV6/T265del, rAAV6/T265del_K531E, rAAV7/T265del, rAAV8/T265del, 
rAAV9/S264del_S266del and rAAV9 capsids packaging CBA-luc were produced 
concurrently and titered together in the same reaction plate via qPCR. Mice were 
individually injected with 1e11vg of each construct, and sacrificed at 10dpi to collect 
heart and liver tissue samples for quantitative analysis. Liver tissue was collected in 
addition to heart as a measure of vector specificity. rAAV1/T265del, rAAV6/T265del, 
rAAV6/T265del_K531E, and rAAV7/T265del each transduced the heart at levels 
identical to rAAV9, while rAAV8/T265del was approximately 5-fold more efficient than 
rAAV9 and rAAV9/S263A_S265del approximately 3-fold less efficient (Figure 3.6a). We 
next wanted to determine whether our mutants preferentially transduced cardiac tissue 
over other organs such as the liver.  All VR1 mutant capsids exhibited greater 
cardiotropism than rAAV9 (Figure 3.6b, c), with the exception of rAAV8/T265del, which 
transduced the liver at an equivalent level as rAAV9. rAAV6/T265del produced the most 
promising cardiotropic profile, transducing the heart approximately 582 times more 
efficiently than the liver (Figure 3.6c) versus rAAV9, which transduced the heart only 2-
fold more efficiently than the liver. Collectively, these data present six new reagents with 
a more favorable cardiotropism than rAAV9.            
To assess the ability of our 265D mutant capsid panel to transduce the liver 
relative to rAAV8, rAAV1/T265D, rAAV2/265D_R585E, rAAV3b/265D_R594A, and 
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rAAV6/T265D_K531E vectors packaging CBA-luc were produced in tandem with 
rAAV8. All constructs were titered on the same qPCR plate and injected into mice at a 
dose of 1e11vg. Mice were sacrificed at 10dpi and samples of liver tissue removed for 
analysis. None of the 265D mutant capsids reached the transduction efficiency of 
rAAV8, though rAAV2/265D_R585E came within <3-fold (Figure 3.6d). rAAV1/T265D 
and rAAV6/T265D_K531E each transduced the liver approximately 8-fold less efficiently 
than rAAV8, and rAAV3b/265D_R594A by approximately 17-fold less efficiency (Figure 
3.6d). Collectively, these results show that while the insertion or substitution of an 
aspartic acid residue into VR1 can substantially enhance hepatic transduction efficiency 
in numerous serotypes, rAAV8 is still superior in transduction of the liver in this mouse 
model.  
 
Cardiotropism of VR1 mutant capsids is enhanced by incorporation of Y->F mutations 
Mutation of select tyrosine residues on the rAAV capsid surface has been shown 
to enhance rAAV transduction efficiency by avoiding the phosphorylation and ultimate 
proteasomal degradation of intracellular capsids before they are able to reach the 
nucleus [185]. We wanted to determine if these mutations could synergize with VR1 
mutant capsids to enhance transduction efficiency while maintaining the biodistributive 
phenotypes imparted by VR1 mutation. As rAAV1 has been the most utilized serotype 
for translational human studies aimed at correcting cardiac and skeletal muscle disease 
[3, 186], an rAAV1 capsid was created to include both Y445F and T265del mutations. 
Though tyrosine-to-phenylalanine mutations have not been previously evaluated in the 
context of rAAV1, Y445F has been proven to enhance transduction efficiency in rAAV6 
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following intramuscular injection [178]. rAAV1 and rAAV6 have >99% homology in 
capsid protein sequence [150], thus it was reasonable to expect that this mutation may 
function similarly in the context of rAAV1. Nevertheless, rAAV6 was also included in this 
analysis. Wild-type rAAV1 and rAAV6 capsids packaging CBA-luc were produced 
concurrently with single and double T265del and Y445F mutant capsids. Mice were 
injected via the tail vein with 1e11vg of each, and heart, liver, and GC tissue samples 
were removed at 10dpi for analysis. In both serotypes, the double T265del_Y445F 
mutant capsids further improved cardiac transduction efficiency: rAAV1/T265del_Y445F 
transduced the heart 66-fold and 9-fold higher than rAAV1 and rAAV1/T265del (Figure 
3.7a), respectively, while rAAV6/T265del_Y445F transduced 30-fold and 3-fold higher 
than rAAV6 and rAAV6/T265del. The double T265del_Y445F mutation led to variable 
effects in GC tissue, wherein transduction was enhanced by 3.5-fold in 
rAAV6/T265del_Y445F versus rAAV6/T265del (Figure 3.7b), and was virtually the 
same between the rAAV1 counterpoints to these mutants. In both serotypes the liver 
detargeting imparted by the VR1 mutant capsids was wholly maintained in the context 
of Y445F mutation. Curiously, the Y445F mutant alone could not enhance the 
transduction efficiency of either rAAV1 or rAAV6 following intravenous delivery, despite 
the fact that in cell culture experiments the mutant enhanced transduction markedly 
over wild-type capsids (data not shown). To our knowledge, these mutants have not 
been previously evaluated following intravenous injection into mice and thus it is difficult 
to speculate why they would not outperform their parental counterparts via this route of 
delivery. Perhaps a tyrosine residue at position 445 is required for successful trafficking 
across barriers imposed by blood vasculature. Altogether, these data suggest that 
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incorporating Y445F into VR1 mutant capsids can further enhance cardiac transduction 
while maintaining a liver-detargeted biodistribution profile. 
 
 
DISCUSSION 
 
We present here a novel capsid engineering method that can be used to improve 
the targeting and transduction of muscle tissue in systemically delivered rAAV. Previous 
observations have shown that disrupting the stability of rAAV1 capsid loop VR1 via the 
deletion of select amino acids significantly enhanced skeletal muscle transduction 
following intramuscular injection [174]. The mutations most efficient at enhancing 
transduction correlated to those that were most disruptive to VR1 intra-loop hydrogen 
bond networks. These observations led us to probe whether the targeted destabilization 
of VR1 in rAAV1 could induce preferential targeting of muscle tissue following 
intravenous administration, and whether this approach could be used to engineer 
additional rAAV serotypes towards producing a similar outcome. Our strategy was 
effective in enhancing the biodistributive properties of five of the nine serotypes studied. 
In rAAV1 and rAAV6 capsids, a robust gain of function in transducing cardiac and/or 
skeletal muscle tissues was observed, while in rAAV7, rAAV8, and rAAV9 capsids, 
native transduction levels were maintained in muscle tissue while liver transduction 
efficiency was dramatically decreased. Significant deleterious effects following VR1 
mutation were noted in the remaining serotypes, including the inability to produce intact 
virions in rAAV4 and rAAV5 and severe transduction deficiencies in rAAV2 and rAAV3b. 
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Thus, our method provides functional insights into capsid topology that can either be 
systematically incorporated or avoided when designing novel vectors. 
Intra-protein hydrogen bond networks regulate functionality and structural 
dynamics in virtually every class of proteins, including numerous viral species (for 
example, see [187]). However, barring the acquisition of empirical structural data, only 
correlative evidence currently supports that hydrogen bond destabilization is the driving 
force behind the improved phenotypes of the VR1 mutant capsids created in this study. 
Nonetheless, the evidence does provide reasonable support of the hypothesis. First, the 
strategy worked as intended in the majority of serotypes tested. Second, rAAV6 
residues S262 and T265 form a hydrogen bond pair that works together to stabilize the 
rest of VR1 (Figure 3.1f), and the individual deletion of either of these residues resulted 
in equivalent biodistributive phenotypes (Figure 3.10c). Third, VR1 stability appears to 
depend on two different sets of hydrogen bond partners in rAAV9 (Figure 3.1h), and the 
desired muscle-tropic biodistribution phenotype could only be obtained following 
mutation of both of them (Figure 3.3g); individual mutations of either residue were 
ineffective (Figure 3.11d). Finally, in rAAV8 only a single hydrogen bond exists in VR1: 
that of the position T265 amino acid side chain hydrogen bonding to itself (Figure 3.1g). 
While the deletion of T265 resulted in substantial detargeting of the liver (Figure 3.3e), 
the removal of the neighboring S266 did not (Figure 3.14). Coupled with the destructive 
effects that VR1 destabilization has on rAAV2, rAAV3b, rAAV4 and rAAV5, the evidence 
suggests that a precisely defined structure for this capsid loop is highly influential to the 
productive advancement of rAAV through its life-cycle. 
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While disruptions to VR1 structure clearly result in vectors with enhanced 
systemic properties, further details behind the mechanism governing these novel 
phenotypes remain elusive. Individual hydrogen bond pairs have been found to control 
capsid stability and infectious efficiency in diverse viral species [188-191] and have 
additionally been hypothesized to modulate rAAV assembly [192]. However, an 
established heat dissociation protocol designed to measure rAAV capsid stability [70] 
revealed no differences between wild-type and VR1 mutant capsids (data not shown). 
Furthermore, a simple increase in capsid dissociability seems unlikely to result in broad 
changes to vector biodistribution. The VR1 loop of rAAV lies at an interface between 
monomeric subunits on the exposed capsid surface and can therefore potentially 
interact with additional proteins. Intra-capsid hydrogen bond networks are known to 
modulate capsid interactions with binding partners, such as during glycan catalysis by 
influenza neuraminidase [193], receptor engagement by human polyomavirus [194], and 
evasion of the anti-viral factor TRIM5α by HIV-2 [195]. VR1 mutation may therefore alter 
capsid stability so as to prevent capsid interactions with a preferred cell surface 
receptor, enabling an alternate entryway into the nucleus. The consistent reduction in 
hepatic vector genome populations of mice administered VR1 deletion mutant capsids 
supports this notion, as does the finding that vector genomes delivered to cardiac cells 
by mutant capsids were far more efficiently expressed than those delivered by wild-type 
counterparts. Furthermore, this concept is not without precedent, as rAAV2 exhibits 
improved muscle targeting and decreased liver transduction when the capsid is mutated 
to eliminate heparin binding [63, 85]. rAAV9 also exhibits a liver-detargeted, 
systemically enhanced phenotype when mutated to reduce galactose binding [87]. It is 
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notable that VR1 mutations have been shown to reduce the ability of rAAV2 and rAAV6 
capsids to bind to heparan sulfate [174]. Additionally, the N-terminal region of VR1 is 
positioned on the capsid in close enough proximity (<3A) to the galactose-binding 
footprint of rAAV9 that direct interactions between the two regions are feasible [96]. 
Such observations bring up intriguing questions as to whether receptors identified for 
different rAAV serotypes in vitro are potential artifacts from passaging through cell 
culture, and whether rAAV could have a far greater in vivo transduction potential than 
previously believed if such artifacts are mutationally ablated. 
From a structural perspective, the observation that VR1 deletion mutations 
render rAAV4 and rAAV5 incapable of producing intact virions is straightforward. In both 
of these serotypes, VR1 forms a relatively short loop that is primarily hydrogen bonded 
to underlying B-sheets. Therefore, disrupting the stability of this region of the capsid 
could conceivably result in gross structural changes that prevent capsid monomers from 
interacting with each other. Understanding why VR1 deletion mutations render rAAV2 
and rAAV3b as transduction deficient is less clear. Despite being unable to transduce 
mouse tissues, rAAV2/S264del and rAAV3b/S262del are able to transduce cells in 
culture (data not shown). Therefore, any deficiencies in the transduction of mouse 
tissues stems from some facet of the in vivo environment. Future experiments aim to 
dissect these observations further. The failure to improve rAAV2 through VR1 amino 
acid deletions was not without merit, however, as it led to the serendipitous discovery 
that insertions of aspartic acid into VR1 produce the opposite phenotype of deletion 
mutations: robust enhancement of hepatic transduction following systemic 
administration of vector.  
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The mechanistic details governing the behavior of VR1 insertion mutants are 
currently unknown. Aspartic acid is a known phosphomimetic and could therefore 
potentially redirect capsid trafficking within the cell. Indeed, serine and threonine 
phosphorylation has been suggested to tag rAAV capsids for proteasomal degradation 
[156]. However, open source phosphorylation-site prediction software (NetPhos2.0) 
does not indicate VR1 (either modified or unmodified) as a site of phosphorylation, and 
data from cell culture experiments utilizing proteasome inhibitor (not shown) do not 
support that the phenotype of 265D mutant capsids is a result of reduced proteasomal 
clearance. Another possibility is that aspartic acid insertion into VR1 produces the 
opposite effect of amino acid deletion: stabilizing the structure of VR1 as opposed to 
destroying it. Aspartic acid residues are well known for their stabilizing effect on protein 
structure through participation in intra-protein interactions such as carbonyl stacking 
[196], salt bridges [197], and hydrogen bond networks [187]. If this were true, it is 
conceivable that while VR1 deletion mutations destabilize this region of the capsid so as 
to prevent interaction with a given receptor, aspartic acid insertions into VR1 instead 
enhance both capsid structural stability and resultant protein:protein interactions. The 
majority of 265D mutant capsids increased vector genome populations in both the liver 
and the GC, suggesting that the 265D mutation enhances cell entry. However, while this 
appears advantageous in the case of hepatic transduction, transduction efficiency in GC 
was not enhanced in the context of the 265D mutation, suggesting that post attachment 
processing of the capsid is also being affected by the mutation.  
In summary, our studies offer new structural insights into the influence of the VR1 
region of the rAAV capsid on transduction efficiency and tissue targeting in vivo. These 
	   78	  
insights allowed the development of two conserved rational engineering strategies that 
improve tissue targeting following systemic administration of vector. At first glance, the 
VR1 deletion mutant capsid collection appears to be the more clinically relevant, as six 
novel vectors were developed that can perform at or above the level of rAAV9 at 
targeting the heart. While this is indeed a valuable advancement in rAAV vectorology, 
the 265D mutant capsid collection should not be overlooked in terms of clinical value. 
Though rAAV8 is consistently considered the best hepatic transducer in mouse models 
[184], and though the 265D capsid collection could not outperform rAAV8 in our study, it 
is also notable that rAAV8 may not be the most ideal vector for translational human 
gene therapy applications. Indeed, both rAAV2 and a variant of rAAV3b have been 
found to infect human hepatocytes with higher efficiency than rAAV8 [155]. Thus, both 
of our VR1 mutant capsid collections have the capacity to expand the reagent pool 
available for either muscle- or liver-oriented gene therapy applications. It is our hope 
that this expansion enables better personalization of gene therapy moving forward, 
perhaps allowing a patient’s preexisting neutralizing antibody profile[5] to aid in 
choosing the best-suited serotype for their individual needs and enhancing the ability to 
readminister vector if necessary.  
 
MATERIALS AND METHODS 
 
Plasmids and viruses. All plasmids were obtained from the University of North 
Carolina Gene Therapy Center Vector Core facility. Virus was made by way of triple 
transfection of HEK293 cells and purified by cesium chloride density ultracentrifugation, 
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as previously described [43]. Viral titer was measured using real time quantitative PCR 
(qPCR) analysis, with the following primer set designed to recognize the luciferase 
transgene: (forward) 5’-AAA AGC ACT CTG ATT GAC AAA TAC-3’ and (reverse) 5’-
CCT TCG CTT CAA AAA ATG GAA C-3’. For each experimental group, relevant viral 
constructs were titered together on the same qPCR plate prior to being used. Site-
directed mutagenesis (Stratagene QuikChange) was used to create nucleotide deletions 
or substitutions. Table 3.3 lists the primer sequences used for all VR1 mutants created 
in this study. Prior to making virus, DNA sequencing was performed to verify that the 
sequence identity of each plasmid used in this work was correct.  
Structural analysis and molecular modeling. Indicated pdb files were processed 
through MolProbity structural validation software (molprobity.biochem.duke.edu) to add 
hydrogen bonds based on electron-cloud x-H bond lengths, using H-bond optimization 
via the inclusion of Asn/Gln/His flips where necessary. Files were then analyzed for all-
atom contacts and geometry, and visualized in KiNG (kinemage.biochem.duke.edu) to 
determine VR1 atoms participating in hydrogen bonds. PDBs were then opened in 
PyMol (pymol.org), shown as stick diagrams with hydrogens visualized, and hydrogen 
bonds identified in KiNG were translated into dashed lines using the measure.  
 
Live-animal studies. Animals were maintained and handled in accordance with 
National Institutes of Health guidelines, under protocols approved by the IACUC at the 
University of North Carolina, Chapel Hill. rAAV variants packaging the CBA-luciferase 
transgene were injected into the tail vein of 6-8 week old female BALB/c mice (Jackson 
Laboratories) at indicated quantities. All injections were performed in 200µL total 
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volume per injection (volume was brought to 200µL using 1XPBS). Luciferase 
transgene expression was visualized using a Xenogen IVIS Lumina imaging system 
(Perkin Elmer/Caliper Life Sciences) following intraperitoneal injection of D-luciferin 
substrate (Nanolight) at 120mg/kg body weight. Bioluminescent image analysis was 
performed using Living Image software (Perkin Elmer/Caliper Life Sciences).  
 
Ex vivo quantification of transgene expression and copy number. To obtain tissue 
samples for analysis via ex vivo luciferase assay, mice were sacrificed at 10dpi and 
indicated organs were harvested and flash frozen. Tissue was homogenized on ice 
using a razor blade, and approximately 50mg of each tissue homogenate was then 
suspended in 250µL of 2X Passive Lysis Buffer (Promega) and lysed mechanically 
using a Tissue Tearor (Cole-Parmer). 35µL of each tissue lysate was then transferred to 
a 96-well plate and mixed with 100µL of D-luciferin substrate (Promega) immediately 
prior to performing luminometric analysis using a Victor2 luminometer (Perkin Elmer). 
The total protein concentration of each tissue lysate was determined by Bradford assay 
(Bio-Rad). Additionally, a ~25mg aliquot of the above generated tissue homogenate was 
processed using a DNeasy kit (Qiagen) to extract host and vector genomic DNA. The 
number of cells was determined using qPCR with the following primers designed 
specific to mouse Lamin (a housekeeping gene): (forward) 5’-GGA CCC AAG GAC TAC 
CTC AAG GG-3’ and (reverse) 5’-AGG GCA CCT CCA TCT CGG AAA C-3’. The 
number of viral genomes per cell was also determined using qPCR with primers 
designed specific to the luciferase transgene, as described above. 
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Figure 3.1. VR1 hydrogen bond networks in various rAAV serotypes. PyMol 
images are focused on capsid loop VR1. Dashed lines represent hydrogen bonds 
present in the crystal structures of rAAV1 (PDB ID, 3NG9), rAAV2 (PDB ID, 1LP3), 
rAAV3b (PDB ID, 3KIC), rAAV4 (PDB ID, 2G8G), rAAV5 (PDB ID, 3NTT), rAAV6 (PDB 
ID, 3OAH), rAAV8 (PDB ID, 2QAO), and rAAV9 (PDB ID, 3UX1). VR1 amino acids 
participating in hydrogen bond networks are depicted as sticks and colored green. 
Amino acids that were mutated for this study are colored cyan. In rAAV1 (a), bonds are 
shown between residues T265 and S262, T265 and A263, T265 and S264, and S264 
and G266. In rAAV2 (b), bonds are shown between residues S264 and G265, and 
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Q263 and A266. In rAAV3b (c), bonds are shown between residues Q263 and A266, 
and Q263 and G265. In rAAV4 (d), bonds are shown between residues L258 and N261. 
In rAAV5 (e), bonds are shown between residues S258 and V255, and S258 and N261. 
In rAAV6 (f), bonds are shown between residues T265 and S262, and S262 and H272. 
In rAAV8 (g), bonds are shown between residues T265 and T265 (residue hydrogen 
bonds to itself). In rAAV9 (h), bonds are shown between residues S263 and G267, and 
S265 and S265 (residue hydrogen bonds to itself). 
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Figure 3.2. Biodistribution of rAAV1 and rAAV6 capsids bearing VR1 
deletion mutations. Live-animal bioluminescent imaging of rAAV1 (a) and rAAV6 (d) 
capsids at 9 days post tail vein injections of 1e11 vector genomes per construct. At 10 
dpi, indicated organs were harvested, lysed and homogenized, and luciferase 
expression and total protein content of lysate quantified (b, e). Values are shown in 
relative light units per milligram total protein (RLU/mg). An indicated subset of organs 
was further processed via qPCR (c, f) to determine number of vector genomes per cell 
genomes (vg/cg). Each data point represents n=3; images are of one representative 
mouse per group. Error bars reflect standard deviation. 
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Figure 3.3. Biodistribution of rAAV7, rAAV8, and rAAV9 capsids bearing 
VR1 deletion mutations. Live-animal bioluminescent imaging of rAAV7 (a), rAAV8 (d), 
and rAAV9 (g) capsids at 9 days post tail vein injections of 1e11 vector genomes per 
construct. At 10 dpi, indicated organs were harvested, lysed and homogenized, and 
luciferase expression and total protein content of lysate quantified (b, e, h). Values are 
shown in relative light units per milligram total protein (RLU/mg). An indicated subset of 
organs was further processed via qPCR (c, f, i) to determine number of vector genomes 
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per cell genomes (vg/cg). Each data point represents n=3; images are of one 
representative mouse per group. Error bars reflect standard deviation. 
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Figure 3.4. Biodistribution of rAAV1, rAAV2, rAAV3b, and rAAV6 capsids 
bearing VR1 insertion/substitution mutations. Live-animal bioluminescent imaging of 
rAAV2 (a), rAAV3b (d), rAAV1 (g), and rAAV6 (j) capsids at 9 days post tail vein 
injections of 1e11 vector genomes per construct. At 10 dpi, indicated organs were 
harvested, lysed and homogenized, and luciferase expression and total protein content 
of lysate quantified (b, e, h, k). Values are shown in relative light units per milligram 
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total protein (RLU/mg). An indicated subset of organs was further processed via qPCR 
(c, f, i, l) to determine number of vector genomes per cell genomes (vg/cg). Each data 
point represents n=3; images are of one representative mouse per group. Error bars 
reflect standard deviation. 
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Figure 3.5. Impact of capsid heparin binding ability on transduction 
efficiency of capsids bearing VR1 insertion/substation mutations. Ex vivo 
luciferase assay results on liver samples taken 10dpi from mice injected with 1e11vg of 
an rAAV2 capsid subset (a) including 265D, heparin-null, and 265D heparin-null 
combination mutants; an rAAV3b capsid subset (b) including 265D, heparin-null, and 
265D heparin-null combination mutants; and an rAAV6 capsid subset (c) including 
265D, heparin-null, and 265D heparin-null combination mutants. Ex vivo luciferase 
assay results on heart, liver, and GC samples taken 10dpi from mice injected with 
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1e11vg of an rAAV6 capsid subset (d) including T265del, heparin-null and T265del 
heparin-null combination mutants. Data represents relative light units normalized per mg 
of protein analyzed (RLU/mg).  Each data point represents n=3; error bars reflect 
standard deviation. 
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Figure 3.6. Comparison of VR1 mutant to wild-type capsid transduction 
efficiency in cardiac and hepatic tissues. Ex vivo luciferase assay results on tissue 
samples taken from the heart (a) and liver (b) at 10dpi of 1e11vg of a panel of VR1 
deletion mutant capsids. Data represented as fold-change relative to values obtained for 
rAAV9, after measuring relative light units per mg of protein analyzed. Ratio of heart to 
liver transduction (c) of organs analyzed in a and b. Ex vivo luciferase assay results on 
liver tissue samples (d) taken at 10dpi of 1e11vg of a panel of 265D mutant capsids. 
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Data represented as fold-change relative to values obtained for rAAV8 after measuring 
relative light units per mg of protein analyzed. Each data point represents n=3; error 
bars reflect standard deviation.  
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Figure 3.7. Transduction efficiency of rAAV1 and rAAV6 capsids bearing 
VR1 mutations in conjunction with tyrosine-to-phenylalanine mutations. Ex vivo 
luciferase assay results on a panel of heart, liver, and GC tissues taken from a panel of 
rAAV1 capsids (a) bearing VR1 deletion mutations alone and in conjunction of Y445F 
mutations, and from a panel of rAAV6 (b) capsids with the equivalent mutations. Data 
represents relative light units normalized per mg of protein analyzed (RLU/mg). Tissue 
samples were taken at 10dpi of 1e11vg per construct. Each data point represents n=3; 
error bars reflect standard deviation. 
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Figure 3.8. VR1 hydrogen bonding networks visualized by KiNG display 
software. Protein main chains are depicted in orange, side chains in light green. 
Hydrogen bonds are shown as dark green clouds, with arrows indicating hydrogen 
bonds present in VR1. VR1 residues are labeled. In panel (a), the following bonds are 
highlighted for rAAV1: HG1 T265 to O S262; O A263 to HG1 T265; OG S264 to H 
T265. In panel (b), the following bonds are highlighted for rAAV2: OG S264 to H G265; 
H A266 to O Q263. In panel (c), the following bonds are highlighted for rAAV3b: O 
Q263 to H A266; O Q263 to H G265. In panel (d), the following bonds are highlighted 
for rAAV4: O L258 to H N261. In panel (e), the following bonds are highlighted for 
rAAV5: H S258 to O V255; O S258 to H N261. In panel (f), the following bonds are 
highlighted for rAAV6: O S264 A to HG S264 A; HG1 T265 to O S262; OG S262 to HD1 
H272. In panel (g), the following bonds are highlighted for rAAV8: HG1 T265 to O T265. 
In panel (h), the following bonds are highlighted for rAAV9:  HG S265 to O S265; H 
G267 to O S263. 
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Figure 3.9. Qualitative biodistribution of VR1 deletion mutant capsids in 
serotypes rAAV2 and rAAV3b. In panels (a) and (b), 1e11vg of each of the indicated 
constructs was administered via the tail vein. Mice were imaged at 10dpi. In panels (c) 
and (d), 5e11vg of each of the indicated constructs was administered via the tail vein. 
Mice were imaged at 10dpi. In all cases N=3 was evaluated; one representative mouse 
from each group is shown. 
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Figure 3.10. Quantitative biodistribution for VR1 deletion mutant rAAV1 and 
rAAV6 capsids. Panels (a) and (b) depict luciferase expression via average RLU/mg 
protein for visceral organs following tail vein injection of 1e11vg of the indicated 
constructs. Panel (c) compares luciferase expression via average RLU/mg protein 
between rAAV6/T262del and rAAV6/T265del in heart, liver and GC. N=3; error bars 
represent standard deviation. 
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Figure 3.11. Quantitative and qualitative biodistribution of VR1 deletion 
mutant rAAV7, rAAV8, and rAAV9 capsids. Panels (a), (b), and (c) depict luciferase 
expression via average RLU/mg protein for visceral organs following tail vein injection of 
1e11vg of the indicated constructs. In panel (d) mice were injected via the tail vein with 
1e11vg per indicated construct and imaged at 10dpi. N=3 for all experiments; error bars 
represent standard deviation. In panel (d) one representative mouse from each group is 
shown. 
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Figure 3.12. Quantitative biodistribution for VR1 265D mutant rAAV1, 
rAAV2, rAAV3b, and rAAV6 capsids. Panels (a), (b), (c) and (d) depict luciferase 
expression via average RLU/mg protein for visceral organs following tail vein injection of 
1e11vg of the indicated constructs. N=3; error bars represent standard deviation. 
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Figure 3.13. Qualitative biodistribution of 265D mutant rAAV8 and rAAV9 
capsids. In panels (a) and (b), 1e11vg of each of the indicated constructs was 
administered via the tail vein. Mice were imaged at 10dpi. In all cases N=3 was 
evaluated; one representative mouse from each group is shown. 
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Figure 3.14. Qualitative biodistribution of rAAV8 and rAAV8/S266del 
capsids. 1e11vg of each of the indicated constructs was administered via the tail vein. 
Mice were imaged at 10dpi. In all cases N=3 was evaluated; one representative mouse 
from each group is shown. 
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Table 3.1. Variable region 1 amino acid sequences and deletion mutations made in 
rAAV1-rAAV9.   
 
 
 
 
Serotype 
 
Variable Region 1 
 
Mutations 
 
rAAV1 
 
262SSASTGASNDNHY273 
 
T265del+++ 
 
rAAV2 
 
262SSQSGAS268 
 
Q263del+, S264del+ 
 
rAAV3b 
 
262SSQSGASNDNHY273 
 
Q263del++ 
 
rAAV4 
 
256ESLQSNTY263 
 
N261del+ 
 
rAAV5 
 
252SGSVDGS258 
 
S258del++ 
 
rAAV6 
 
262SSASTGASNDNHY273 
 
S262del++, T265del+ 
 
rAAV7 
 
n/a 
 
T265del 
 
rAAV8 
 
263NGTSGGAT270 
 
T265del+ 
 
rAAV9 
 
261SNSTSGGSS269 
S263del++, S265del+, 
S263del_S265del+++ 
                             + indicates number of hydrogen bonds hypothesized to be broken following mutation 
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Table 3.2. Variable region 1 amino acid sequences and aspartic acid insertion and 
substitution mutations made in select rAAV capsids.   
 
 
 
 
 
Serotype 
 
Variable Region 1 
 
Mutations 
 
rAAV1 
                    * 
262SSASDGASNDNHY273 
 
T265D 
 
rAAV2 
                    * 
262SSQSDGAS268 
 
265D 
 
rAAV3b 
* 
262SSQSDGASNDNHY273 
 
266D 
 
rAAV6 
* 
262SSASDGASNDNHY273 
 
T265D 
 
rAAV8 
* 
263NGDSGGAT270 
 
T265D 
 
rAAV9 
  * 
261SNSDSGGSS269 
 
S265D 
                     Bolded text indicates conserved primary amino acid sequence; asterisks highlight aspartic acid mutations. 
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Table 3.3. Site-directed mutagenesis primers used in this study. 
 
 
 
 
Construct 
 
 
Primer Sequence (5’ -> 3’) 
pXR1/T265del* ctc cag tgc ttc agg ggc cag caa cg 
pXR1/T265D* gca atc tcc agt gct tca gac ggg gcc agc aac g 
pXR1/Y445F* cat cga cca gta cct gta ttt cct gaa cag aac tca 
pXR2/Q263del caa aca aat ttc cag ctc agg agc ctc g 
pXR2/S264del caa att tcc agc caa gga gcc tcg aac g 
pXR3b/Q263del caa gca aat ctc cag ctc agg agc ttc 
pXR3b/266D ctc cag cca atc aga cgg agc ttc aaa cg 
pXR3b/R594A cag ctc cca cga ctg caa ctg tca atg atc 
pXR4/N261del gag cct gca gtc cac cta caa cgg 
pXR5/258del ccg tcg acg gaa acg cca acg cc 
pXR6/S262del gca aat ctc cgc ttc aac ggg gg 
pXR7/T265del caa atc tcc agt gaa gca ggt agt acc 
pXR8/T265del ctc caa cgg gtc ggg agg agc 
pXR8/T265D caa atc tcc aac ggg gac tcg gga gga gcc acc 
pXR8/S266del tct cca acg gga cag gag gag cca acc 
pXR9/S263del Caa gca aat ctc cag cac atc tgg agg 
pXR9/S265del ctc caa cag cac agg agg atc ttc aaa tg 
pXR9/T265D caa gca aat ctc caa cag cga ctc tgg agg atc ttc aaa tg 
pXR9/S263A_S265del gca aat ctc caa cgc cac agg agg atc ttc aaa tga c 
 
*indicates that same primer sequence was used for pXR1 and pXR6 constructs
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CHAPTER IV: 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
The use of rAAV in human gene therapy applications has grown exponentially in 
recent years, leading to several notable instances of clinical success. The many clinical 
trials that do not necessarily “succeed”, however, clarify the obstacles that need to be 
conquered in order to advance rAAV into a widely usable therapeutic. The goal of this 
dissertation was to identify components of the rAAV capsid that can be modified so as 
to improve the clinical translatability of rAAV as a vector. Specifically, our aim was to 
improve the transduction phenotype of rAAV in muscle tissue. This aim is timely given 
the many recent clinical trials that are either attempting to cure disorders affecting 
muscle tissues directly (e.g., heart failure [186], the muscular dystrophies [133]) or that 
are trying to employ skeletal muscle as an intermediary to secrete proteins into the 
bloodstream for the alleviation of disorders such as hemophilia B [108] and AAT 
deficiency [2]. By far the most significant obstacle impeding the success of current 
muscle-oriented gene therapy applications is inadequate therapeutic transgene 
expression following transduction with rAAV [139]. The principal way that this issue has 
been surmounted thus far has been through the administration of extraordinarily high 
doses of vector [139] that often must be delivered over a series of one hundred 
injections or more [140]. Even in light of these dosing protocols, subtherapeutic 
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transgene expression remains a formidable barrier to successful gene therapy [2, 139, 
140, 148].   
To develop rAAV vectors that can overcome this barrier, we investigated the 
structure-function relationship of a loop on the capsid surface known as VR1. Previous 
work performed in our group [133, 142] suggested that VR1 is a key determinant of 
transduction efficiency in rAAV2. In Chapter 2, we extended these findings through 
mutagenic dissection of VR1 in the context of the more clinically relevant rAAV1 to 
create a panel of modified capsids that 1.) enhanced expression of the luciferase 
reporter transgene by up to 139-fold following injection into skeletal muscle tissue 
(Figure 2.1), 2.) maintained this transduction enhancement consistently over time 
(Figure 2.1), and 3.) improved serum concentrations of the secreted therapeutic 
transgene AAT relative to those obtained from delivery with unmodified rAAV1 (Figure 
2.7). These novel capsids have significant implications for patient dosing protocols and 
vector production costs moving forward. Following computational analysis of the rAAV1 
capsid crystal structure, we concluded the above work by putting forth the hypothesis 
that these rAAV1 capsid mutations induced regional instability in VR1 by interrupting 
intra-capsid hydrogen bonding networks, and that this destabilization was the driving 
force behind the enhanced transduction phenotypes that were obtained. 
In Chapter 3, we tested this hypothesis by computationally analyzing additional 
serotypes to visualize their VR1 hydrogen bonding networks and creating a panel of 
mutations to disrupt said networks in each. In all capsids that were structurally 
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amenable to the proposed mutations, we observed robust and specific targeting of 
cardiac and skeletal muscle following intravenous injection (Figures 3.2 and 3.3). This 
muscle-tropic phenotype was accompanied by a concurrent loss of transduction in 
hepatic tissues, which is the default target of all naturally occurring rAAV serotypes. 
Additionally, in several serotypes transduction was not only confined to muscle tissue, 
but transduction efficiency was also significantly enhanced there. For instance, a 9027-
fold increase in the transduction of GC muscle tissue was observed following luciferase 
reporter transgene delivery with one of our engineered VR1 capsids (Figure 3.5) versus 
its wild-type counterpart. This panel of capsids not only has direct implications for 
patient dosing but also may further facilitate a shift in the methodology of rAAV delivery 
as whole, from an intensive set of multiple intramuscular injections to a single injection 
through a peripheral vein. Though in the absence of empirical structural data we cannot 
prove that the phenotype of these mutant capsids is due to the disruption of the 
indicated hydrogen bond networks, it is notable that in a functional capacity our 
hypothesis worked. 
While the chief consequence of our rational design strategy is the provision of 
new rAAV reagents for translational studies, important insights into structure-function 
relationships within the capsid were obtained from this work. One of the more intriguing 
findings was that the region of the capsid that harbors VR1 functions in concert with the 
region that harbors the heparin binding receptor footprint to govern rAAV transduction in 
vivo. These regions of the capsid are too distant from each other to form any sort of 
direct interactions (Figure 2.3). Though capsid geometry suggests the feasibility of the 
VR1 region and the heparin binding region functioning as competitors for cell surface 
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receptors (Figure 2.3), the fact that changes to VR1 directly impact the capsid’s affinity 
for heparin (Figure 2.5) suggests that far-ranging allosteric changes occur within the 
capsid in response to VR1 mutation. This concept is not without precedent – for 
example, a single lysine-to-arginine mutation in the capsid of Cowpea chlorotic mottle 
virus was shown via crystallography to alter 660 separate intersubunit interactions per 
viral capsid [191]. Historically, features of the capsid surface have been interpreted to 
function as singular entities (i.e., “the receptor binding region of the capsid”). Therefore, 
future crystallographic analysis of VR1 mutant capsids may provide important insights 
into how distal regions of the capsid affect each other on a structural level, which will 
certainly add a level of refinement to future efforts in rational design. 
We have not yet determined a mechanism behind the phenotype of our VR1 
mutant capsids beyond a structural interpretation of their behavior. For instance, we 
cannot state whether receptor binding is being altered, or whether the mutant capsids 
traffic through the cytoplasm more efficiently than their unmodified parents. One of the 
chief complicating factors towards these endeavors is that none of the VR1 mutant 
capsids outperform their parental counterparts in a cell culture setting (many different 
cell lines were tested, including primary cultures of mouse and human liver and cardiac 
cells). In fact, many of the mutant capsids are deficient in producing any measurable 
transduction in vitro (data not shown). The level of complexity in trying to determine a 
precise mechanism governing the behavior of VR1 mutant capsids using only in vivo 
experimentation cannot be overstated.  
In an attempt to gain at least some insight into whether the gain of function 
observed with VR1 mutant capsids stemmed from increased vector transgene 
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populations within transduced host cells, transgene numbers within tissue samples were 
quantified. However, depending upon route of administration, discrepancies were found 
amongst these populations. For example, in Chapter 2, which focused on intramuscular 
delivery of capsids, we found increased transgene populations within mice that were 
administered VR1 mutant capsids. However, in Chapter 3, which focused on 
intravenous delivery of capsids, no consistent correlations were found between 
transgene populations and transduction efficiency in any given capsid variant. To 
determine whether these inconsistencies were due to punctate transgene delivery 
patterns within sampled tissues (i.e., perhaps initial qPCR analysis was performed on a 
transgene-enriched portion of a tissue sample), great strides were made to compare 
measurements within highly homogenized tissue samples, as well as in samples taken 
from several different areas of a given tissue. Regardless of our approach, clear 
relationships between transgene population and transduction efficiency still did not 
emerge.  
Unfortunately, even if experiments such as above did produce a correlation 
between transgene populations and transduction efficiency, we would still be unable to 
conclude whether these resulted from increased cell entry of VR1 mutant capsids or 
enhanced trafficking of these capsids within the cell. To do so would require intensive 
separation of different intracellular components and analysis of the quantity of vector 
genomes within each. This would be technically challenging using current techniques. 
Additionally, it is possible that VR1 mutant capsids travel through entirely different 
pathways depending upon their route of administration. For example, transduction 
efficiencies of VR1 deletion mutant capsids were enriched in muscle tissue following 
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either intramuscular or intravenous injection (Figures 2.1 and 3.2), whereas VR1 
insertion and substitution mutant capsids were enriched in muscle transduction only 
following intramuscular injection (Figures 2.1 and 3.4), and preferentially transduced 
the liver following systemic administration (Figure 3.4).   
The coadministration of pharmaceutical agents in tandem with rAAV would be an 
alternative method of probing how intracellular capsid trafficking may be altered in 
response to VR1 mutation [157]. For example, previous studies have shown that the 
phosphorylation of select serine and threonine residues on the capsid surface can lead 
to proteasomal clearance of capsids, and that mutation of such residues to non-
phosphorylable counterparts leads capsids to avoid this pathway [156], thus enhancing 
transduction. As the majority of mutations made in this study were to serine and 
threonine residues within VR1, we did perform preliminary experiments to quantify 
transduction efficiency following coadministration of vector and proteasome inhibitor 
(not shown) and concluded that the behavior of VR1 mutant capsids was not related to 
this pathway. This is not wholly surprising, as a simple avoidance of ubiquitination 
seems insufficient in explaining gross changes in vector biodistribution. Beyond this, 
drugs that iteratively affect each step of intracellular viral processing (e.g., receptor 
endocytosis, endosomal trafficking, nuclear entry) could be delivered to mice concurrent 
with VR1 mutant capsids. This has been a common method of probing rAAV behavior in 
cell culture [157]. However, the ethics of using large populations of animals for such 
experimentation would need to be considered, especially in light of the fact that 
determining a precise mechanism of action for these capsids is not necessary towards 
translating their use into the clinical setting. Furthermore, as VR1 mutant capsids do not 
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outperform parental counterparts in cell culture, it is entirely possible that the processes 
that influence their enhanced transduction phenotype in vivo are occurring before the 
capsids ever enter the cell (e.g., interactions with serum factors, enhancements to 
transcytosis across the vasculature).  
Due to its many attractive qualities as a gene therapy vector, along with its stable 
safety record in human clinical trials, it is likely that rAAV will remain a prominent choice 
in the treatment of intractable genetic disorders for quite a long time. Though several 
clinical trials have produced promising results following rAAV-mediated gene therapy, it 
will be necessary to tackle several important impediments to success if we are to 
expand rAAV’s therapeutic repertoire. The work in this dissertation sought to improve 
the transduction efficiency of rAAV in vivo and to refine the ability to target specific 
tissues following intravenous administration of vector. Through structural analysis and 
molecular dissection of the rAAV capsid, we gained novel insights into structure-function 
relationships within the capsid protein that led to the generation of a panel of novel 
capsids that can be immediately used in translational studies. Furthermore, an 
engineering strategy was developed that should theoretically be able to synergize with 
many other existing capsid variants, which will aid in the continued development of next 
generation rAAV vectors. Finally, the conserved nature of our approach has widespread 
implications for the clinic, particularly in terms of refining a patient personalized 
approach to gene therapy and the ability to substantially enhance therapeutic transgene 
expression while potentially reducing clinical dosing protocols. Moving forward, it is our 
sincere hope that the design strategy elucidated herein will broaden the clinical pathway  
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for rAAV-mediated gene therapy so that many more patients can finally experience 
relief from intractable disease. 
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